P1 1216782

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

October 07, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: *60/367,089*
FILING DATE: *March 22, 2002*
RELATED PCT APPLICATION NUMBER: *PCT/US03/08880*

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

G. Montgomery

W. MONTGOMERY
Certifying Officer

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)

PATENT APPLICATION SERIAL NO. _____

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FEE RECORD SHEET

03/28/2002 AADOF01 00000097 60367089
01 FC:114 160.00 OP

PTO-1556
(5/87)

*U.S. Government Printing Office: 2001 — 481-697/59173

03-23-02 A/PROV

Customer Number: 000959

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney
Docket No. BGI-152-1

In re the application of: Yocum, *et al.*

For: Methods and Organisms for Production of B6 Vitamers

Commissioner for Patents
Box Provisional Patent Application
Washington, D.C. 20231

CERTIFICATION UNDER 37 CFR 1.10

Date of Deposit: March 22, 2002 Mailing Label Number: EL 939 868 587 US

I hereby certify that this Cover Sheet for Filing Provisional Application (37 C.F.R. §1.51(2)(i)) and the documents referred to as attached therein are being deposited with the United States Postal Service on the date indicated above in an envelope as "Express Mail Post Office to Addressee" service under 37 CFR 1.10 and addressed to the Commissioner for Patents, Box Provisional Patent Application, Washington, D.C. 20231.

Larry Taylor
Name of Person Mailing Paper

Larry Taylor
Signature of Person Mailing Paper

COVER SHEET FOR FILING PROVISIONAL PATENT APPLICATION

Dear Sir:

The accompanying application, entitled "Methods and Organisms for Production of B6 Vitamers," is a provisional patent application under 37 C.F.R. §1.51(c) and §1.53(c).

1. ☒ The name(s) and address(es) of the inventor(s) of this application is/are as follows:

1	Yocum	R.	Rogers	4 Orchard Lane, Lexington, Massachusetts 02420
2	Williams	Mark	K.	58 School Street, Revere, Massachusetts 02151
3	Pero	Janice	G.	20 Solomon Pierce Road, Lexington, Massachusetts 02420

2. ☒ The following documents are enclosed:

- ☒ 28 page(s) of Specification
- ☒ 6 page(s) of Claims
- ☒ 1 page(s) of Abstract
- ☒ 12 page(s) of Sequence Listing
- ☒ 7 sheets of Informal Drawings; and
- ☒ Return postcard.

3. ☒ The fee for filing this provisional application, as set forth in 37 CFR 1.16(k), is $160.00.

   a. ☒ A check for this filing fee is enclosed.
   b. ☐ Charge the filing fee to Deposit Account No. ___________.
   (A duplicate copy of this sheet is enclosed.)
   c. ☐ The filing fee is not being paid at this time.

4. ☒ Please charge any fee deficiencies associated with this filing to Deposit Account No. 12-0080. A duplicate copy of this sheet is enclosed.

5. ☒ Please address all future communications to: **Customer Number: 000959** whose address is:

Lahive & Cockfield, LLP
28 State Street
Boston, MA 02109

and direct telephone calls to: Elizabeth A. Hanley, (617) 227-7400

Respectfully submitted,

March 22, 2002
Date

Debra J. Milasincic, Esq.
Reg. No. 46,931
Attorney for Applicants

LAHIVE & COCKFIELD, LLP
28 State Street
Boston, MA 02109
Tel. (617) 227-7400

METHODS AND ORGANISMS FOR PRODUCTION OF B6 VITAMERS

Background of the Invention

Vitamin B6, also known as pyridoxine or pyridoxol (PN), or one of a number of closely related compounds, is an essential dietary nutrient for most, if not all, animals, while many micro-organisms (bacteria, fungi, algae, etc.) and plants are capable of synthesizing their own vitamin B6 or compound(s) related to vitamin B6. When an animal ingests PN or a related compound that has vitamin B6 activity, the compound is converted ultimately into pyridoxal phosphate (PLP) and/or pryidoxamine phosphate (PMP), which are the active forms of vitamin B6 in all living organisms. PLP acts as a cofactor for many important or essential enzymes in all living organisms, including transaminases, racemases, and decarboxylases. PLP and PMP are easily interconverted by ubiquitous transaminases.

Vitamin B6 is of commercial importance in vitamin pills, pharmaceutical applications, and as an animal feed additive that enhances growth or desirable growth characteristics in farm and domestic animals. The currently used commercial process for producing vitamin B6 is a synthetic chemical process. However, a fermentation process using a microorganism (see US Patent application No. 09/667,569, filed September 21, 2000, hereby incorporated in its entirety by reference) or a biosynthetic process using a plant species can be more cost effective in the long run, and may be environmentally more attractive.

The biosynthetic pathway for PLP in *E. coli* has been elucidated (reviewed in Mittengruber, G., (2001) J. *Mol. Microbiol. Biotechnol.* 3(1): 1-20; Cane, D.E., et al. (2000) *J. Am. Chem. Soc.* 122: 4213-4214; Man, T-K, et al., (1996) *J. Bacteriol.* 178: 2445-2449). Enzymes encoded by the genes *epd, pdxB, pdxF*, and *pdxA* lead to synthesis of the precursor 1-hydroxy-3-amino acetone phosphate from erythrose-4-phosphate and glutamate. The enzyme encoded by *dxs* leads to the precursor 5'-deoxyxylulose phosphate from glycolytic intermediates. The enzyme encoded by *pdxJ* then catalyzes the chemical coupling of the two precursors to give pyridoxol phosphate (also called pyridoxine phosphate or PNP). PNP is then oxidized to the active form, PLP, by the enzyme encoded by *pdxH*. This biosynthetic pathway to PLP in *E. coli*, as well as closely related pathways, are referred to herein as the Type A Pathway. Partially characterized mutants of *E. coli* have been described that produce about three- to seven-fold more vitamin B_6-related compounds than the parent strain (Dempsey and Arcement (1971) J. Bacteriol. 107(2): 580-582). Partially characterized mutants of *B. subtilis* have been reported that produce 1 - 5 mg/l vitamin B_6, but it was not stated what level the

parent strain produced (Pflug, W., and Lingens, F., (1978) Hoppe-Seyler's Z. Physiol. Chem. 359: 559-570). Notably, these organisms were not recombinantly produced.

A second biosynthetic pathway for vitamin B6, referred to herein as the Type B pathway, may exist in some organisms other than *E. coli* (Mittengruber, G., (2001) *J. Mol. Microbiol. Biotechnol.* 3(1):1-20). In particular, some fungi (for example from the genera *Cercospora, Neurospora, Aspergillus* and *Saccharomyces*), some bacteria (for example *B. subtilis* and *Staphylococcus aureus*), and all plants for which data exists do not contain any genes that are highly homologous to *E. coli pdxA* and *pdxJ*. Instead, these organisms contain genes that are homologous to *Cercospora* genes named *SOR* (or *SNZ*) and *SNO*. In *Saccharomyces*, these homologs are called *PDX1* and *PDX2*, respectively, and in *B. subtilis*, these homologs are named *yaaD* and *yaaE*, respectively. In *B. subtilis*, there have been no reports as to whether *yaaD* or *yaaE* are actually involved in PLP biosynthesis. Protein or DNA sequence homology alone is not sufficient to establish biological function. For example, *B. subtilis* contains a gene, *yhaF*, that encodes a protein that is significantly homologous to *E. coli pdxF*. However, when *yhaF* is mutated, the resulting mutant *B. subtilis* strain is a serine auxotroph, but not a PL auxotroph (*see* Example 3, below). Thus, the identification of a gene or genes involved in PLP biosynthesis in any given organism can not be done using sequence homology alone.

Results from ^{13}C and ^{15}N labeling studies suggest that the precursors that provide the carbon and nitrogen atoms in PL and related compounds are different in *E. coli* and *Saccharomyces cerevisiae* (Gupta, R., et al. (2001) *J. Am Chem. Soc.* 123: 11353-11359; Tayuza, K., et al. (1995) *Biochim. Biophys. Acta* 1244: 113-116.) However, the identity of the precursors for PL and related compounds in *S. cerevisiae* is not yet known. Since most micro-organisms for which the entire genome sequence is known (for example *E. coli, S. cerevisiae* and *B. subtilis*) have either *pdxA* and *pdxJ* homologs or *SOR* and *SNO* homologs, but not both, it appears that most organisms that are capable of synthesizing PLP have either the well characterized Type A Pathway (for example *E. coli, Salmonella typhimurium*, and many other genera), or a distinctly different and incompletely characterized pathway, *e.g.*, the Type B Pathway. Specifically, members of the genera *Cercospora, Neurospora, Aspergillus, Saccharomyces, Bacillus, Arabidopsis*, and many other genera, appear to have a Type B pathway, and are lacking genes involved in the Type A Pathway. The intermediate compounds in the Type B Pathway have not yet been elucidated, although the final product must be PLP (as for the Type A Pathway) or PMP, since these are the active forms of vitamin B6 in all known organisms.

Summary of the Invention

The present invention is based, at least in part, on the discovery of key enzyme-encoding genes of the B6 vitamer biosynthetic pathways in *Bacillus subtilis*. In particular, the invention is based, at least in part, on the discovery that the *yaaD* and *yaaE* genes of *B. subtilis* are required for B6 vitamer synthesis. Deletion of a portion of the *yaaD* and *yaaE* genes (which are adjacent in an operon, *e.g.*, the *yaaDE* operon) leads to PL auxotrophy. Overexpression of the *yaaDE* operon or the deregulation of the expression of the *yaaD* or *yaaE* genes leads to significantly increased production of B6 vitamers in, *e.g.*, *B. subtilis* strains. The *B. subtilis yaaDE* operon is required for pyridoxal phosphate (PLP) biosynthesis, an active form of vitamin B6 in all living organisms. The present invention describes that the expression of the *B. subtilis yaaDE* operon is a rate limiting step for production of compounds related to vitamin B6 in a wild type strain.

Accordingly, the present invention features methods of producing B6 vitamers, including, but not limited to, pyridoxine (or pyridoxol (PN)), pyridoxal (PL), pyridoxamine (PM), or the 5' phosphorylated derivatives of any of the three aforementioned compounds (PNP, PLP, and PMP), using organisms in which the B6 vitamer pathway has been manipulated such that B6 vitamers are produced. Such methods include culturing a microorganism that overexpresses at least one B6 vitamer biosynthetic enzyme (*e.g.*, at least one of the *yaaD* or *yaaE* gene products), under conditions such that the B6 vitamer is produced. The production methods of the present invention further can include recovering the B6 vitamer.

The instant invention also features genetically modified organisms (*i.e.*, organisms that contain one or more modifications or mutations in the genome) that are capable of producing significantly more of a B6 vitamer than an unmodified parent organism. In particular, this invention features micro-organisms (including, for example, but not limited to, bacteria, yeasts, fungi, and algae) or macro-organisms such as plants that, when genetically modified, produce an increased amount, *e.g.*, at least about 10-fold more of a B6 vitamer, than the unmodified parent organism. Specific examples are given herein in which *Bacillus subtilis* and *Escherichia coli* strains have been genetically modified such that they produce significant amounts of a B6 vitamer. Accordingly, the present invention features organisms that have been genetically modified to increase the activity of one or more enzymes that catalyze(s) a step in the biosynthesis of a B6 vitamer, such that B6 vitamer production from said modified organism is increased compared to B6 production in an unmodified parent organism.

Yet another aspect of the invention features recombinant microorganisms which overexpress at least one *Bacillus* (*e.g.*, *B. subtilis*) B6 vitamer biosynthetic

enzyme (*e.g.*, at least one of the *yaaD* or *yaaE* gene products) are described. In one embodiment, the recombinant microorganism is Gram positive (*e.g.*, microorganisms belonging to the genus *Bacillus*, *Cornyebacterium*, *Lactobacillus*, *Lactococci* or *Streptomyces*). In another embodiment, the recombinant microorganism is Gram negative. Particularly preferred is a *Bacillus* recombinant microorganism (*e.g.*, *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Bacillus subtilis*, *Bacillus pumilus*, *Bacillus halodurans*, and the like).

Recombinant vectors that contain genes encoding *Bacillus* B6 vitamer biosynthetic enzymes, *e.g.*, *yaaD* or *yaaE* genes, are also described.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

Brief Description of the Drawings

Figure 1 depicts the chemical structures of vitamin B6 and related compounds.

Figure 2 depicts the biosynthetic pathway for PLP in *E. coli*.

Figure 3 depicts the standard curves generated by *Saccharomyces unarum* strain ATCC 9080 after feeding serial dilutions of PN, PL, and PM (as described in Example 1).

Figure 4 is a schematic representation of the plasmid pDX1F.

Figure 5 is a schematic representation of the plasmid pDX11F.

Figure 6 is a schematic representation of the plasmid pDX14R.

Figure 7 is a schematic representation of the plasmid pDX17R.

Detailed Description of the Invention

The present invention is based, at least in part, on the identification of *Bacillus* (*e.g.*, *B. subtilis*) genes that encode essential enzymes of the B6 vitamer biosynthetic pathway. In particular, the present invention features methods based on manipulation of the B6 vitamer biosynthetic pathway in a microorganism such that certain desirable compounds are produced.

In particular, the invention is based, at least in part, on the discovery that the *yaaD* and y*aaE* genes of *B. subtilis* are required for B6 vitamer synthesis, including, but not limited to, pyridoxine (or pyridoxol (PN)), pyridoxal (PL), pyridoxamine (PM), or the 5' phosphorylated derivatives of any of the three aforementioned compounds (PNP, PLP, and PMP). The *yaaD* and *yaaE* genes are adjacent on an operon, *e.g.*, the *yaaDE* operon. The *yaaD* and *yaaE* genes encode the YaaD and Yaa E proteins,

respectively. Overexpression of the *yaaDE* operon with a strong constitutive promoter or the deregulation of the expression of the *yaaD* or *yaaE* gene(s) leads to significantly increased production of B6 vitamers. These quantities are significantly higher relative to the associated parent strains than those reported in previous studies, which have employed mutant *E. coli* strains (Dempsey and Arcement (1971) *J. Bacteriol.* 107 (2): 580-582), or mutant *B. subtilis* strains (Pflug, W., and Lingens, F., (1978) Hoppe-Seyler's Z. Physiol. Chem. 359: 559-570).

Accordingly, the present invention features organisms that have been genetically modified to increase the activity of one or more enzymes that catalyze a step in the biosynthesis of a B6 vitamer, such that B6 vitamer production from the modified organism is increased compared to B6 production in an unmodified parent organism. In one embodiment, B6 vitamer production is at least ten-fold higher than from the unmodified parent organism. In another embodiment, the organism is genetically modified to overexpress one or more genes that encodes an enzyme that catalyzes a step in the biosynthesis of a B6 vitamer, *e.g., yaaD* or *yaaE*. The organism may be, for example, *B. subtilis*.

The present invention also features methods of producing a B6 vitamer comprising culturing a microorganism that has been genetically modified to overexpress one or more genes that encodes an enzyme that catalyzes a step in the biosynthesis of a B6 vitamer, such that B6 vitamer production from said modified organism is increased compared to B6 production in an unmodified parent organism, under conditions such that the B6 vitamer is produced. The B6 vitamer may then be subsequently recovered. Overproduction of the rate limiting enzyme for B6 vitamer production in any organism that is capable of producing B6 vitamers will lead to overproduction of B6 vitamers.

The terms "B6 vitamer" or "B6 vitamers," as used herein, shall refer to any compound or mixture of compounds that has any biological activity in any biological assay for vitamin B6. B6 vitamers include, but are not limited to, pyridoxine (also called pyridoxol or PN), pyridoxal (PL), pyridoxamine (PM), the 5' phosphorylated derivatives of any of the three aforementioned compounds (PNP, PLP, and PMP), and any derivative or related compound that can be converted to the active forms (PLP or PMP) in a test organism. Thus, for example, the acetate esters or other esters of any of the available hydroxyl groups of any of the aforementioned six compounds, and which are likely to be hydrolyzed by specific or non-specific esterases, are included in B_6 vitamers. Also, various salts, such as hydrochloride salts, of any of the aforementioned compounds are included in B6 vitamers.

The term "B6 vitamer biosynthetic pathway" includes the biosynthetic pathway involving B6 vitamer biosynthetic enzymes (*e.g.*, polypeptides encoded by

biosynthetic enzyme-encoding genes), compounds (*e.g.*, precursors, substrates, intermediates or products), cofactors and the like utilized in the formation or synthesis of B6 vitamers. The term "B6 vitamer biosynthetic pathway" includes the biosynthetic pathway leading to the synthesis of B6 vitamers in a microorganism (*e.g.*, *in vivo*) as well as the biosynthetic pathway leading to the synthesis of B6 vitamers *in vitro*.

A "biological assay for a B6 vitamer" includes, for example, any assay that is capable of quantifying B6 vitamer activity by measuring growth of an organism that requires the feeding of a B6 vitamer (*i.e.*, a compound that the fed organism can convert into PLP or PMP) for growth. Samples to be assayed are diluted serially in an appropriate medium and fed to the appropriate organism. Standard curves are generated by serially diluting known amounts of PL, PN, or PM, and feeding these dilutions to the test organism. By comparing dilutions of the unknown samples to the standard curves, total B6 vitamer activity can be determined, for example as PL equivalents if PL was used to generate the standard curve.

Various aspects of the invention are described in further detail in the following subsections.

I. Genes Encoding Various B6 Vitamer Biosynthetic Enzymes

In one embodiment, the present invention features targeting or modifying various biosynthetic genes or enzymes of the B6 vitamer biosynthetic pathway. In particular, the invention features modifying various enzymatic activities associated with said pathways by modifying or altering the genes encoding said biosynthetic enzymes.

The term "gene", as used herein, includes a nucleic acid molecule (*e.g.*, a DNA molecule or segment thereof) that, in an organism, can be separated from another gene or other genes, by intergenic DNA (*i.e.*, intervening or spacer DNA which naturally flanks the gene and/or separates genes in the chromosomal DNA of the organism). Alternatively, a gene may slightly overlap another gene (*e.g.*, the 3' end of a first gene overlapping the 5' end of a second gene), said overlapping genes separated from other genes by intergenic DNA. A gene may direct synthesis of an enzyme or other protein molecule (*e.g.*, may comprise coding sequences, for example, a contiguous open reading frame (ORF) which encodes a protein) or may itself be functional in the organism. A gene in an organism, may be clustered in an operon, as defined herein, said operon being separated from other genes and/or operons by the intergenic DNA. An "isolated gene", as used herein, includes a gene which is essentially free of sequences which naturally flank the gene in the chromosomal DNA of the organism from which the gene is derived (*i.e.*, is free of adjacent coding sequences which encode a second or

distinct protein, adjacent structural sequences or the like) and optionally includes 5' and 3' regulatory sequences, for example promoter sequences and/or terminator sequences. In one embodiment, an isolated gene includes predominantly coding sequences for a protein (*e.g.*, sequences which encode *Bacillus* proteins). In another embodiment, an isolated gene includes coding sequences for a protein (*e.g.*, for a *Bacillus* protein) and adjacent 5' and/or 3' regulatory sequences from the chromosomal DNA of the organism from which the gene is derived (*e.g.*, adjacent 5' and/or 3' *Bacillus* regulatory sequences). Preferably, an isolated gene contains less than about 10 kb, 5 kb, 2 kb, 1 kb, 0.5 kb, 0.2 kb, 0.1 kb, 50 bp, 25 bp or 10 bp of nucleotide sequences that naturally flank the gene in the chromosomal DNA of the organism from which the gene is derived.

The term "operon" includes at least two adjacent genes or ORFs, optionally overlapping in sequence at either the 5' or 3' end of at least one gene or ORF. The term "operon" includes a coordinated unit of gene expression that contains a promoter and possibly a regulatory element associated with one or more adjacent genes or ORFs (*e.g.*, structural genes encoding enzymes, for example, biosynthetic enzymes). Expression of the genes (*e.g.*, structural genes) can be coordinately regulated, for example, by regulatory proteins binding to the regulatory element or by anti-termination of transcription. The genes of an operon (*e.g.*, structural genes) can be transcribed to give a single mRNA that encodes all of the proteins.

A "gene having a mutation" or "mutant gene" as used herein, includes a gene having a nucleotide sequence which includes at least one alteration (*e.g.*, substitution, insertion, deletion) such that the polypeptide or protein encoded by said mutant exhibits an activity that differs from the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. In one embodiment, a gene having a mutation or mutant gene encodes a polypeptide or protein having an increased activity as compared to the polypeptide or protein encoded by the wild-type gene, for example, when assayed under similar conditions (*e.g.*, assayed in microorganisms cultured at the same temperature). As used herein, an "increased activity" or "increased enzymatic activity" is one that is at least 5% greater than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene, preferably at least 5-10% greater, more preferably at least 10-25% greater and even more preferably at least 25-50%, 50-75% or 75-100% greater than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. Ranges intermediate to the above-recited values, *e.g.*, 75-85%, 85-90%, 90-95%, are also intended to be encompassed by the present invention. As used herein, an "increased activity" or "increased enzymatic activity" can also include an activity that is at least 1.25-fold greater than the activity of the polypeptide or protein encoded by the wild-type gene, preferably at least 1.5-fold

greater, more preferably at least 2-fold greater and even more preferably at least 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold or greater than the activity of the polypeptide or protein encoded by the wild-type gene.

In another embodiment, a gene having a mutation or mutant gene encodes a polypeptide or protein having a reduced activity as compared to the polypeptide or protein encoded by the wild-type gene, for example, when assayed under similar conditions (*e.g.*, assayed in microorganisms cultured at the same temperature). A mutant gene also can encode no polypeptide or have a reduced level of production of the wild-type polypeptide. As used herein, a "reduced activity" or "reduced enzymatic activity" is one that is at least 5% less than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene, preferably at least 5-10% less, more preferably at least 10-25% less and even more preferably at least 25-50%, 50-75% or 75-100% less than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. Ranges intermediate to the above-recited values, *e.g.*, 75-85%, 85-90%, 90-95%, are also intended to be encompassed by the present invention. As used herein, a "reduced activity" or "reduced enzymatic activity" can also include an activity that has been deleted or "knocked out" (*e.g.*, approximately 100% less activity than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene).

Activity can be determined according to any well accepted assay for measuring activity of a particular protein of interest. Activity can be measured or assayed directly, for example, measuring an enzymatic or biological activity of a protein isolated or purified from a cell or microorganism. Alternatively, an activity can be measured or assayed within a cell or mocroorganism or in an extracellular medium. For example, assaying for a mutant gene (*i.e.*, said mutant encoding a reduced enzymatic activity) can be accomplished by expressing the mutated gene in a microorganism, for example, a mutant microorganism in which the enzyme is temperature-sensitive, and assaying the mutant gene for the ability to complement a temperature sensitive (Ts) mutant for enzymatic activity. A mutant gene that encodes an "increased enzymatic activity" can be one that complements the Ts mutant more effectively than, for example, a corresponding wild-type gene. A mutant gene that encodes a "reduced enzymatic activity" is one that complements the Ts mutant less effectively than, for example, a corresponding wild-type gene.

It will be appreciated by the skilled artisan that even a single substitution in a nucleic acid or gene sequence (*e.g.*, a base substitution that encodes an amino acid change in the corresponding amino acid sequence) can dramatically affect the activity of an encoded polypeptide or protein as compared to the corresponding wild-type

polypeptide or protein. A mutant gene (*e.g.*, encoding a mutant polypeptide or protein), as defined herein, is readily distinguishable from a nucleic acid or gene encoding a protein homologue in that a mutant gene encodes a protein or polypeptide having an altered activity, optionally observable as a different or distinct phenotype in a microorganism expressing said mutant gene or producing said mutant protein or polypeptide (*i.e.*, a mutant microorganism) as compared to a corresponding microorganism expressing the wild-type gene. By contrast, a protein homologue has an identical or substantially similar activity, optionally phenotypically indiscernible when produced in a microorganism, as compared to a corresponding microorganism expressing the wild-type gene. Accordingly it is not, for example, the degree of sequence identity between nucleic acid molecules, genes, protein or polypeptides that serves to distinguish between homologues and mutants, rather it is the activity of the encoded protein or polypeptide that distinguishes between homologues and mutants: homologues having, for example, low (*e.g.*, 30-50% sequence identity) sequence identity yet having substantially equivalent functional activities, and mutants, for example sharing 99% sequence identity yet having dramatically different or altered functional activities.

In a preferred embodiment, the genes of the present invention are derived from *Bacillus*. The term "derived from *Bacillus*" or "*Bacillus*-derived" includes a gene which is naturally found in microorganisms of the genus *Bacillus*. In another preferred embodiment, the genes of the present invention are derived from a microorganism selected from the group consisting of *Bacillus subtilis, Bacillus lentimorbus, Bacillus lentus*, *Bacillus firmus*, *Bacillus pantothenticus*, *Bacillus amyloliquefaciens*, *Bacillus cereus*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus pumilus*, *Bacillus thuringiensis*, *Bacillus halodurans*, and other Group 1 *Bacillus* species, for example, as characterized by 16S rRNA type. In another preferred embodiment, the gene is derived from *Bacillus brevis* or *Bacillus stearothermophilus*. In another preferred embodiment, the genes of the present invention are derived from a microorganism selected from the group consisting of *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Bacillus subtilis*, and *Bacillus pumilus*. In a particularly preferred embodiment, the gene is derived from *Bacillus subtilis* (*e.g.*, is *Bacillus subtilis*-derived). The term "derived from *Bacillus subtilis*" or "*Bacillus subtilis*-derived" includes a gene which is naturally found in the microorganism *Bacillus subtilis*. Included within the scope of the present invention are *Bacillus*-derived genes (*e.g.*, *B. subtilis*-derived genes), for example, *Bacillus* or *B. subtilis yaaD* or *yaaE* genes.

II. Recombinant Nucleic Acid Molecules and Vectors

The present invention further features recombinant nucleic acid molecules (*e.g.*, recombinant DNA molecules) that include genes described herein (*e.g.*, isolated genes), preferably *Bacillus* genes, more preferably *Bacillus subtilis* genes, even more preferably *Bacillus subtilis* B6 vitamer biosynthetic genes. The term "recombinant nucleic acid molecule" includes an isolated nucleic acid molecule (*e.g.*, a DNA molecule) that has been altered, modified or engineered such that it differs in nucleotide sequence from the native or natural nucleic acid molecule from which the recombinant nucleic acid molecule was derived (*e.g.*, by addition, deletion or substitution of one or more nucleotides). Preferably, a recombinant nucleic acid molecule (*e.g.*, a recombinant DNA molecule) includes an isolated gene of the present invention operably linked to regulatory sequences. The phrase "operably linked to regulatory sequence(s)" means that the nucleotide sequence of the gene of interest is linked to the regulatory sequence(s) in a manner which allows for expression (*e.g.*, enhanced, increased, constitutive, basal, attenuated, decreased or repressed expression) of the gene, preferably expression of a gene product encoded by the gene (*e.g.*, when the recombinant nucleic acid molecule is included in a recombinant vector, as defined herein, and is introduced into a microorganism). A "recombinant organism" is any organism that contains a recombinant nucleic acid molecule.

The term "regulatory sequence" includes nucleic acid sequences that affect (*e.g.*, modulate or regulate) expression of other nucleic acid sequences (*i.e.*, genes). In one embodiment, a regulatory sequence is included in a recombinant nucleic acid molecule in a similar or identical position and/or orientation relative to a particular gene of interest as is observed for the regulatory sequence and gene of interest as it appears in nature, *e.g.*, in a native position and/or orientation. For example, a gene of interest can be included in a recombinant nucleic acid molecule operably linked to a regulatory sequence which accompanies or is adjacent to the gene of interest in the natural organism (*e.g.*, operably linked to "native" regulatory sequences (*e.g.*, to the "native" promoter). Alternatively, a gene of interest can be included in a recombinant nucleic acid molecule operably linked to a regulatory sequence which accompanies or is adjacent to another (*e.g.*, a different) gene in the natural organism. Alternatively, a gene of interest can be included in a recombinant nucleic acid molecule operably linked to a regulatory sequence from another organism. For example, regulatory sequences from other microbes (*e.g.*, other bacterial regulatory sequences, bacteriophage regulatory sequences and the like) can be operably linked to a particular gene of interest.

In one embodiment, a regulatory sequence is a non-native or non-naturally-occurring sequence (*e.g.*, a sequence which has been modified, mutated,

substituted, derivatized, deleted including sequences which are chemically synthesized). Preferred regulatory sequences include promoters, enhancers, termination signals, anti-termination signals, ribosome binding sites and other expression control elements (*e.g.*, sequences to which repressors or inducers bind and/or binding sites for transcriptional and/or translational regulatory proteins, for example, in the transcribed mRNA). Such regulatory sequences are described, for example, in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory,* Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in a microorganism (*e.g.*, constitutive promoters and strong constitutive promoters), those which direct inducible expression of a nucleotide sequence in a microorganism (*e.g.*, inducible promoters, for example, xylose inducible promoters) and those which attenuate or repress expression of a nucleotide sequence in a microorganism (*e.g.*, attenuation signals or repressor sequences). It is also within the scope of the present invention to regulate expression of a gene of interest by removing or deleting regulatory sequences. For example, sequences involved in the negative regulation of transcription can be removed such that expression of a gene of interest is enhanced.

In one embodiment, a recombinant nucleic acid molecule of the present invention includes a nucleic acid sequence or gene that encodes at least one bacterial gene product (*e.g.*, a B6 vitamer biosynthetic enzyme, *e.g.*, the gene product of *yaaD* and/or *yaaE*) operably linked to a promoter or promoter sequence. Preferred promoters of the present invention include *Bacillus* promoters and/or bacteriophage promoters (*e.g.*, bacteriophage which infect *Bacillus*). In one embodiment, a promoter is a *Bacillus* promoter, preferably a strong *Bacillus* promoter (*e.g.*, a promoter associated with a biochemical housekeeping gene in *Bacillus* or a promoter associated with a glycolytic pathway gene in *Bacillus*). In another embodiment, a promoter is a bacteriophage promoter. In a preferred embodiment, the promoter is from the bacteriophage SP01. In a particularly preferred embodiment, a promoter is selected from the group consisting of P_{15}, P_{26}, or P_{veg} having for example, the following respective sequences:

GCTATTGACGACAGCTATGGTTCACTGTCCACCAACCAAAACTGTGCTCAGT
ACCGCCAATATTTCTCCCTTGAGGGGTACAAAGAGGTGTCCCTAGAAGAGAT
CCACGCTGTGTAAAAATTTTACAAAAAGGTATTGACTTTCCCTACAGGGTGT
GTAATAATTTAATTACAGGCGGGGGCAACCCCGCCTGT (SEQ ID NO:9),
GCCTACCTAGCTTCCAAGAAAGATATCCTAACAGCACAAGAGCGGAAAGAT
GTTTTGTTCTACATCCAGAACAACCTCTGCTAAAATTCCTGAAAAATTTTGC
AAAAAGTTGTTGACTTTATCTACAAGGTGTGGTATAATAATCTTAACAACAG
CAGGACGC (SEQ ID NO:10); and

GAGGAATCATAGAATTTTGTCAAAATAATTTTATTGACAACGTCTTATTAAC GTTGATATAATTTAAATTTTATTTGACAAAAATGGGCTCGTGTTGTACAATA AATGTAGTGAGGTGGATGCAATG (SEQ ID NO:11). Additional preferred promoters include *tef* (the translational elongation factor (TEF) promoter) and *pyc* (the pyruvate carboxylase (PYC) promoter), which promote high level expression in *Bacillus* (*e.g., Bacillus subtilis*). Additional preferred promoters, for example, for use in Gram positive microorganisms include, but are not limited to, *amy* and SPO2 promoters. Additional preferred promoters, for example, for use in Gram negative microorganisms include, but are not limited to, *tac*, *trp*, *tet*, *trp-tet*, *lpp*, *lac*, *lpp-lac*, *lacIQ*, T7, T5, T3, *gal*, *trc*, *ara*, SP6, λ-PR or λ-PL.

In another embodiment, a recombinant nucleic acid molecule of the present invention includes a terminator sequence or terminator sequences (*e.g.*, transcription terminator sequences). The term "terminator sequences" includes regulatory sequences that serve to terminate transcription of mRNA. Terminator sequences (or tandem transcription terminators) can further serve to stabilize mRNA (*e.g.*, by adding structure to mRNA), for example, against nucleases.

In yet another embodiment, a recombinant nucleic acid molecule of the present invention includes sequences which allow for detection of the vector containing said sequences (*i.e.*, detectable and/or selectable markers), for example, genes that encode antibiotic resistance or sequences that overcome auxotrophic mutations, for example, *trpC*, fluorescent markers, drug markers, and/or colorimetric markers (*e.g.*, *lacZ*/β-galactosidase). In yet another embodiment, a recombinant nucleic acid molecule of the present invention includes an artificial ribosome binding site (RBS) or a sequence that becomes transcribed into an artificial RBS. The term "artificial ribosome binding site (RBS)" includes a site within an mRNA molecule (*e.g.*, coded within DNA) to which a ribosome binds (*e.g.*, to initiate translation) which differs from a native RBS (*e.g.*, a RBS found in a naturally-occurring gene) by at least one nucleotide. Preferred artificial RBSs include about 5-6, 7-8, 9-10, 11-12, 13-14, 15-16, 17-18, 19-20, 21-22, 23-24, 25-26, 27-28, 29-30 or more nucleotides of which about 1-2, 3-4, 5-6, 7-8, 9-10, 11-12, 13-15 or more differ from the native RBS (*e.g.*, the native RBS of a gene of interest, for example, the native *yaaD* RBS GAAATCATATAACTATACCTTGATTAGGGGGACCAAGAAATG (SEQ ID NO:12) or the native *yaaE* RBS CAAGAACGCGGCTGGTAAGAACATAGGAGCGCTGCTGACATG (SEQ ID NO:13)).

Preferably, nucleotides that differ are substituted such that they are identical to one or more nucleotides of an ideal RBS when optimally aligned for

comparisons. Artificial RBSs can be used to replace the naturally-occurring or native RBSs associated with a particular gene. Artificial RBSs preferably increase translation of a particular gene. Preferred artificial RBSs (*e.g.*, RBSs for increasing the translation of *yaaE*, for example, of *B. subtilis*) are set forth in Table 1, below.

Table 1: Preferred Ribosome Binding Sites

	10 20	SEQ ID NO:
Native_yaaD	---GAAATCATATAACTATACCTTGATTAGGGGGACC-AAGAAATG	12
Native_yaaE	CAAGAACGCGGCTGGTAAGAACAT----AGGAGCGCTGCTGACATG	13
IDEAL_RBS	--------------TCTAGAAAGG----AGGTG-----A-------	14
RBS1	--------------TCTAGAAGG-----AGGAG-----AAAACATG	15
RBS2	--------------TCTAGAGG------AGGAG-----AAAACATG	16
RBS101	----------------TAAGAACAA---AGGAGGAGAGCTGACATG	17
RBS103	----------------TAAGAAGAA---AGGAGGTGAGCTGACATG	18
RBS102	----------------TAAGAACAG---AGGAGGAGAGCTGACATG	19

The present invention further features vectors (*e.g.*, recombinant vectors) that include nucleic acid molecules (*e.g.*, genes or recombinant nucleic acid molecules comprising said genes) as described herein. The term "recombinant vector" includes a vector (*e.g.*, plasmid, phage, phasmid, virus, cosmid or other purified nucleic acid vector) that has been altered, modified or engineered such that it contains greater, fewer or different nucleic acid sequences than those included in the native or natural nucleic acid molecule from which the recombinant vector was derived. Preferably, the recombinant vector includes a biosynythetic enzyme-encoding gene or recombinant nucleic acid molecule including said gene, operably linked to regulatory sequences, for example, promoter sequences, terminator sequences and/or artificial ribosome binding sites (RBSs), as defined herein. In another embodiment, a recombinant vector of the present invention includes sequences that enhance replication in bacteria (*e.g.*, replication-enhancing sequences). In one embodiment, replication-enhancing sequences are derived from *E. coli*. In another embodiment, replication-enhancing sequences are derived from pBR322. In another embodiment, replication-enhancing sequences are derived from pSC101.

In yet another embodiment, a recombinant vector of the present invention includes antibiotic resistance sequences. The term "antibiotic resistance sequences" includes sequences which promote or confer resistance to antibiotics on the host organism (*e.g.*, *Bacillus*). In one embodiment, the antibiotic resistance sequences are selected from the group consisting of *cat* (chloramphenicol resistance) sequences, *tet* (tetracycline resistance) sequences, *erm* (erythromycin resistance) sequences, *neo*

(neomycin resistance) sequences, *kan* (kanamycin resistance) and *spec* (spectinomycin resistance) sequences. Recombinant vectors of the present invention can further include homologous recombination sequences (*e.g.*, sequences designed to allow recombination of the gene of interest into the chromosome of the host organism). For example, *bpr*, *vpr*, and/or *amyE* sequences can be used as homology targets for recombination into the host chromosome. It will further be appreciated by one of skill in the art that the design of a vector can be tailored depending on such factors as the choice of microorganism to be genetically engineered, the level of expression of gene product desired and the like.

IV. Recombinant Microorganisms

The present invention further features microorganisms, *i.e.*, recombinant microorganisms, that include vectors or genes (*e.g.*, wild-type and/or mutated genes) as described herein. As used herein, the term "recombinant microorganism" includes a microorganism (*e.g.*, bacteria, yeast cell, fungal cell, etc.) that has been genetically altered, modified or engineered (*e.g.*, genetically engineered) such that it exhibits an altered, modified or different genotype and/or phenotype (*e.g.*, when the genetic modification affects coding nucleic acid sequences of the microorganism) as compared to the naturally-occurring microorganism from which it was derived.

In one embodiment, a recombinant microorganism of the present invention is a Gram positive organism (*e.g.*, a microorganism which retains basic dye, for example, crystal violet, due to the presence of a Gram-positive wall surrounding the microorganism). In a preferred embodiment, the recombinant microorganism is a microorganism belonging to a genus selected from the group consisting of *Bacillus*, *Cornyebacterium*, *Lactobacillus*, *Lactococci* and *Streptomyces*. In a more preferred embodiment, the recombinant microorganism is of the genus *Bacillus*. In another preferred embodiment, the recombinant microorganism is selected from the group consisting of *Bacillus subtilis, Bacillus lentimorbus*, *Bacillus lentus*, *Bacillus firmus*, *Bacillus pantothenticus*, *Bacillus amyloliquefaciens*, *Bacillus cereus*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus pumilus*, *Bacillus thuringiensis*, *Bacillus halodurans*, and other Group 1 *Bacillus* species, for example, as characterized by 16S rRNA type. In another preferred embodiment, the recombinant microorganism is *Bacillus brevis* or *Bacillus stearothermophilus*. In another preferred embodiment, the recombinant microorganism is selected from the group consisting of *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Bacillus subtilis*, and *Bacillus pumilus*.

In another embodiment, the recombinant microorganism is a Gram negative (excludes basic dye) organism. In a preferred embodiment, the recombinant

microorganism is a microorganism belonging to a genus selected from the group consisting of *Salmonella, Escherichia, Klebsiella, Serratia,* and *Proteus*. In a more preferred embodiment, the recombinant microorganism is of the genus *Escherichia*. In an even more preferred embodiment, the recombinant microorganism is *Escherichia coli*. In another embodiment, the recombinant microorganism is *Saccharomyces* (*e.g.*, *S. cerevisiae*).

A preferred "recombinant" microorganism of the present invention is a microorganism having a deregulated B6 vitamer biosynthesis pathway or enzyme. The term "deregulated" or "deregulation" includes the alteration or modification of at least one gene in a microorganism that encodes an enzyme in a biosynthetic pathway, such that the level or activity of the biosynthetic enzyme in the microorganism is altered or modified. Preferably, at least one gene that encodes an enzyme in a biosynthetic pathway is altered or modified such that the gene product is enhanced or increased. The phrase "deregulated pathway" can also include a biosynthetic pathway in which more than one gene that encodes an enzyme in a biosynthetic pathway is altered or modified such that the level or activity of more than one biosynthetic enzyme is altered or modified. The ability to "deregulate" a pathway (*e.g.*, to simultaneously deregulate more than one gene in a given biosynthetic pathway) in a microorganism in some cases arises from the particular phenomenon of microorganisms in which more than one enzyme (*e.g.*, two or three biosynthetic enzymes) are encoded by genes occurring adjacent to one another on a contiguous piece of genetic material termed an "operon" (defined herein). Due to the coordinated regulation of genes included in an operon, alteration or modification of the single promoter and/or regulatory element can result in alteration or modification of the expression of more than one gene product encoded by the operon. Alteration or modification of the regulatory element can include, but is not limited to removing the endogenous promoter and/or regulatory element(s), adding strong promoters, inducible promoters or multiple promoters or removing regulatory sequences such that expression of the gene products is modified, modifying the chromosomal location of the operon, altering nucleic acid sequences adjacent to the operon or within the operon such as a ribosome binding site, increasing the copy number of the operon, modifying proteins (*e.g.*, regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of the operon and/or translation of the gene products of the operon, or any other conventional means of deregulating expression of genes routine in the art (including but not limited to use of antisense nucleic acid molecules, for example, to block expression of repressor proteins). Deregulation can also involve altering the coding region of one or more genes

to yield, for example, an enzyme that is feedback resistant or has a higher or lower specific activity.

In another preferred embodiment, a recombinant microorganism is designed or engineered such that at least one B6 vitamer biosynthetic enzyme, is overexpressed. The term "overexpressed" or "overexpression" includes expression of a gene product (*e.g.*, a biosynthetic enzyme) at a level greater than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated. In one embodiment, the microorganism can be genetically designed or engineered to overexpress a level of gene product greater than that expressed in a comparable microorganism which has not been engineered.

Genetic engineering can include, but is not limited to, altering or modifying regulatory sequences or sites associated with expression of a particular gene (*e.g.*, by adding strong promoters, inducible promoters or multiple promoters or by removing regulatory sequences such that expression is constitutive), modifying the chromosomal location of a particular gene, altering nucleic acid sequences adjacent to a particular gene such as a ribosome binding site, increasing the copy number of a particular gene, modifying proteins (*e.g.*, regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of a particular gene and/or translation of a particular gene product, or any other conventional means of deregulating expression of a particular gene routine in the art (including but not limited to use of antisense nucleic acid molecules, for example, to block expression of repressor proteins). Genetic engineering can also include deletion of a gene, for example, to block a pathway or to remove a repressor. In embodiments featuring microorganisms having deleted genes, the skilled artisan will appreciate that at least low levels of certain compounds may be required to be present in or added to the culture medium in order that the viability of the microorganism is not compromised. Often, such low levels are present in complex culture media as routinely formulated. Moreover, in processes featuring culturing microorganisms having deleted genes cultured under conditions such that commercially or industrially attractive quantities of product are produced, it may be necessary to supplement culture media with slightly increased levels of certain compounds.

In another embodiment, the microorganism can be physically or environmentally manipulated to overexpress a level of gene product greater than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated. For example, a microorganism can be treated with or cultured in the presence of an agent known or suspected to increase transcription of a particular gene and/or translation of a particular gene product such that transcription

and/or translation are enhanced or increased. Alternatively, a microorganism can be cultured at a temperature selected to increase transcription of a particular gene and/or translation of a particular gene product such that transcription and/or translation are enhanced or increased.

V. Culturing and Fermenting Recombinant Microorganisms

The term "culturing" includes maintaining and/or growing a living microorganism of the present invention (*e.g.*, maintaining and/or growing a culture or strain). In one embodiment, a microorganism of the invention is cultured in liquid media. In another embodiment, a microorganism of the invention is cultured in solid media or semi-solid media. In a preferred embodiment, a microorganism of the invention is cultured in media (*e.g.*, a sterile, liquid media) comprising nutrients essential or beneficial to the maintenance and/or growth of the microorganism (*e.g.*, carbon sources or carbon substrate, for example carbohydrate, hydrocarbons, oils, fats, fatty acids, organic acids, and alcohols; nitrogen sources, for example, peptone, yeast extracts, meat extracts, malt extracts, soy flour, urea, ammonium sulfate, ammonium chloride, ammonium nitrate and ammonium phosphate; phosphorus sources, for example, phosphoric acid, sodium and potassium salts thereof; trace elements, for example, magnesium, iron, manganese, calcium, copper, zinc, boron, molybdenum, and/or cobalt salts; as well as growth factors such as amino acids, vitamins, and the like).

Preferably, microorganisms of the present invention are cultured under controlled pH. The term "controlled pH" includes any pH which results in production of the desired product. In one embodiment microorganisms are cultured at a pH of about 7. In another embodiment, microorganisms are cultured at a pH of between 6.0 and 8.5. The desired pH may be maintained by any number of methods known to those skilled in the art.

Also preferably, microorganisms of the present invention are cultured under controlled aeration. The term "controlled aeration" includes sufficient aeration (*e.g.*, oxygen) to result in production of the desired product. In one embodiment, aeration is controlled by regulating oxygen levels in the culture, for example, by regulating the amount of oxygen dissolved in culture media. Preferably, aeration of the culture is controlled by agitating the culture. Agitation may be provided by a propeller or similar mechanical agitation equipment, by revolving or shaking the culture vessel (*e.g.*, tube or flask) or by various pumping equipment. Aeration may be further controlled by the passage of sterile air or oxygen through the medium (*e.g.*, through the

fermentation mixture). Also preferably, microorganisms of the present invention are cultured without excess foaming (*e.g.*, *via* addition of antifoaming agents).

Moreover, microorganisms of the present invention can be cultured under controlled temperatures. The term "controlled temperature" includes any temperature which results in production of the desired product (*e.g.*, a B6 vitamer). In one embodiment, controlled temperatures include temperatures between 15°C and 95°C. In another embodiment, controlled temperatures include temperatures between 15°C and 70°C. Preferred temperatures are between 20°C and 55°C, more preferably between 30°C and 50°C.

Microorganisms can be cultured (*e.g.*, maintained and/or grown) in liquid media and preferably are cultured, either continuously or intermittently, by conventional culturing methods such as standing culture, test tube culture, shaking culture (*e.g.*, rotary shaking culture, shake flask culture, etc.), aeration spinner culture, or fermentation. In a preferred embodiment, the microorganisms are cultured in shake flasks. In a more preferred embodiment, the microorganisms are cultured in a fermentor (*e.g.*, a fermentation process). Fermentation processes of the present invention include, but are not limited to, batch, fed-batch and continuous processes or methods of fermentation. The phrase "batch process" or "batch fermentation" refers to a closed system in which the composition of media, nutrients, supplemental additives and the like is set at the beginning of the fermentation and not subject to alteration during the fermentation, however, attempts may be made to control such factors as pH and oxygen concentration to prevent excess media acidification and/or microorganism death. The phrase "fed-batch process" or "fed-batch" fermentation refers to a batch fermentation with the exception that one or more substrates or supplements are added (*e.g.*, added in increments or continuously) as the fermentation progresses. The phrase "continuous process" or "continuous fermentation" refers to a system in which a defined fermentation media is added continuously to a fermentor and an equal amount of used or "conditioned" media is simultaneously removed, preferably for recovery of the desired product (*e.g.*, a B6 vitamer). A variety of such processes have been developed and are well-known in the art.

The phrase "culturing under conditions such that a desired compound is produced" includes maintaining and/or growing microorganisms under conditions (*e.g.*, temperature, pressure, pH, duration, etc.) appropriate or sufficient to obtain production of the desired compound or to obtain desired yields of the particular compound being produced. For example, culturing is continued for a time sufficient to produce the desired amount of a compound (*e.g.*, a B6 vitamer). Preferably, culturing is continued for a time sufficient to substantially reach suitable production of the compound (*e.g.*, a

time sufficient to reach a suitable concentration of a B6 vitamer). In one embodiment, culturing is continued for about 12 to 24 hours. In another embodiment, culturing is continued for about 24 to 36 hours, 36 to 48 hours, 48 to 72 hours, 72 to 96 hours, 96 to 120 hours, 120 to 144 hours, or greater than 144 hours. The methodology of the present invention can further include a step of recovering a desired compound (*e.g.*, a B6 vitamer). The term "recovering" a desired compound includes extracting, harvesting, isolating or purifying the compound from culture media. Recovering the compound can be performed according to any conventional isolation or purification methodology known in the art including, but not limited to, treatment with a conventional resin (*e.g.*, anion or cation exchange resin, non-ionic adsorption resin, etc.), treatment with a conventional adsorbent (*e.g.*, activated charcoal, silicic acid, silica gel, cellulose, alumina, etc.), alteration of pH, solvent extraction (*e.g.*, with a conventional solvent such as an alcohol, ethyl acetate, hexane and the like), dialysis, filtration, concentration, crystallization, recrystallization, pH adjustment, lyophilization and the like. For example, a compound can be recovered from culture media by first removing the microorganisms from the culture. The resulting solutions are then passed through or over a cation exchange resin to remove cations and/or through or over an anion exchange resin to purify or concentrate the desired product. The resulting compound can subsequently be converted to a salt (*e.g.*, a chloride or sulfate salt) by ion exchange.

Preferably, a desired compound of the present invention is "extracted," "isolated" or "purified" such that the resulting preparation is substantially free of other media components (*e.g.*, free of media components and/or fermentation byproducts). The language "substantially free of other media components" includes preparations of the desired compound in which the compound is separated from media components or fermentation byproducts of the culture from which it is produced. In one embodiment, the preparation has greater than about 80% (by dry weight) of the desired compound (*e.g.*, less than about 20% of other media components or fermentation byproducts), more preferably greater than about 90% of the desired compound (*e.g.*, less than about 10% of other media components or fermentation byproducts), still more preferably greater than about 95% of the desired compound (*e.g.*, less than about 5% of other media components or fermentation byproducts), and most preferably greater than about 98-99% desired compound (*e.g.*, less than about 1-2% other media components or fermentation byproducts). When the desired compound has been derivatized to a salt, the compound is preferably further free of chemical contaminants associated with the formation of the salt. When the desired compound has been derivatized to an alcohol, the compound is preferably further free of chemical contaminants associated with the formation of the alcohol.

In an alternative embodiment, the desired compound is not purified from the microorganism, for example, when the microorganism is biologically non-hazardous (*e.g.*, safe). For example, the entire culture (or culture supernatant) can be used as a source of product (*e.g.*, crude product). In one embodiment, the culture (or culture supernatant) is used without modification. In another embodiment, the culture (or culture supernatant) is concentrated. In yet another embodiment, the culture (or culture supernatant) is dried or lyophilized.

Preferably, a production method of the present invention results in production of the desired compound, *e.g.*, a B6 vitamer, at a significantly high yield. The phrase "significantly high yield" includes a level of production or yield which is sufficiently elevated or above what is usual for comparable production methods, for example, which is elevated to a level sufficient for commercial production of the desired product (*e.g.*, production of the product at a commercially feasible cost). In one embodiment, the invention features a production method that includes culturing a recombinant microorganism under conditions such that the desired product (*e.g.*, a B6 vitamer) is produced at a level greater than 5 mg/L. In another embodiment, the invention features a production method that includes culturing a recombinant microorganism under conditions such that the desired product (*e.g.*, a B6 vitamer) is produced at a level greater than 10 mg/L. In another embodiment, the invention features a production method that includes culturing a recombinant microorganism under conditions such that the desired product (*e.g.*, a B6 vitamer) is produced at a level greater than 50 mg/L. In yet another embodiment, the invention features a production method that includes culturing a recombinant microorganism under conditions such that the desired product (*e.g.*, a B6 vitamer) is produced at a level greater than 150 mg/L.

Depending on the biosynthetic enzyme or combination of biosynthetic enzymes manipulated, it may be desirable or necessary to provide (*e.g.*, feed) microorganisms of the present invention at least one biosynthetic precursor such that the desired compound or compounds are produced. The term "biosynthetic precursor" or "precursor" includes an agent or compound which, when provided to, brought into contact with, or included in the culture medium of a microorganism, serves to enhance or increase biosynthesis of the desired product. In one embodiment, the biosynthetic precursor or precursor is glutamine. In another embodiment, the biosynthetic precursor or precursor is ribose. The amount of glutamine or ribose added is preferably an amount that results in a concentration in the culture medium sufficient to enhance productivity of the microorganism (*e.g.*, a concentration sufficient to enhance production of a B6 vitamer). The term "excess ribose or glutamine" includes ribose or glutamine levels increased or higher that those routinely utilized for culturing the microorganism in

question. For example, culturing the *Bacillus* microorganisms described in the instant Examples is routinely done in the presence of about 0-5 g/L ribose or glutamine. Accordingly, excess ribose or glutamine levels can include levels of about 5-10 g/L or more preferably about 5-20 g/L ribose or glutamine. Biosynthetic precursors of the present invention can be added in the form of a concentrated solution or suspension (*e.g.*, in a suitable solvent such as water or buffer) or in the form of a solid (*e.g.*, in the form of a powder). Moreover, biosynthetic precursors of the present invention can be added as a single aliquot, continuously or intermittently over a given period of time.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are incorporated herein by reference.

EXAMPLES

EXAMPLE 1: Biological assay for B6 vitamers using *Saccharomyces uvarum*.

Quantitation of B6 vitamers in supernatants of cultures of micro-organisms or extracts of organisms that have been genetically modified to increase production of B6 vitamers is conveniently done using *Saccharomyces uvarum* (formerly and still often named *S. carlsbergensis*) strain ATCC 9080 as the indicator strain or test organism. The method is essentially that described in the Difco Manual (1984, Difco Laboratories, Detroit, MI, 10th Edition, pp. 1104-1106), with the modification that 50 mg/liter of streptomycin sulfate is added to the liquid growth medium for the test organism. However, any other appropriate indicator organism may be used, together with a medium that is appropriate for that organism that is free of B6 vitamers. For example, an *E. coli pdxB* mutant can be used in a standard minimal medium that is well known in the art, such as M9 glucose minimal medium (Miller, J., (1972) Experiments in Molecular Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).

When using *S. uvarum* strain ATCC 9080 as the indicator strain, Bacto Pyridoxine Y Medium (Difco Laboratories, available through VWR Scientific, Inc.), supplemented with 50 mg/liter streptomycin sulfate, is used for the serial dilutions, and PN, PL, or PM is used to generate the standard curve. The responses to these three standard compounds are almost identical to each other with *S. uvarum* strain ATCC 9080 (Figure 3).

EXAMPLE 2: Deletion of a portion of the *yaaDE* operon in *B. subtilis*.

The *SOR* and *SNO* genes of *Cercospora nicotianae* were originally identified by mutations that lead to hypersensitivity to singlet oxygen-generating reagents (Ehrenschaft, M., *et al.* (1999) *Proc. Natl. Acad. Sci. USA* 96: 9347-9378). Mutations in either of these genes also lead to PL auxotrophy. The protein sequences obtained from translation of the *SOR* and *SNO* open reading frames were used as homology probes to search through the *B. subtilis* genome sequence using the BLAST homology search program of the Subtilist website. The SOR protein was significantly homologous to the YaaD protein, and the SNO protein was significantly homologous to the YaaE protein. Moreover, the genes encoding the YaaD and YaaE proteins (namely *yaaD* and *yaaE*) occur adjacent to each other on the *B. subtilis* chromosome as a two gene operon.

General methods for growth, storage, transformation, and molecular biology *of B. subtilis* strains are given in Harwood, C., and Cutting, S. (1990), Molecular Biological Methods for *Bacillus*, John Wiley and Sons, New York, NY, hereby

incorporated in its entirety by reference. The *yaaDE* operon DNA sequence was amplified using the Polymerase Chain Reaction (PCR) with Pfu Turbo DNA polymerase (Stratagene, Inc., used according to the manufacturer's instructions). The DNA primers used were RY395 (SEQ ID NO:1) and RY396 (SEQ ID NO:2). RY395, the upstream primer, introduces an *XbaI* site and artificial ribosome binding site. RY396, the downstream primer, introduces a *BamHI* site. The template DNA was chromosomal DNA isolated form wild type *B. subtilis* strain PY79. The blunt ended PCR product was ligated into the *EcoRV* site of pGEM5Zf(+) (Promega, Inc.) to give plasmid pAN368. Next, a gram positive chloramphenicol resistance gene on a blunt DNA fragment was ligated into pAN368 that had been cut with *HpaI*, to give plasmid pDX1F (SEQ ID NO:5, Figure 4). pDX1F therefore is deleted for a portion of *yaaD* and a portion of *yaaE*. pDX1F was used to transform wild type *B. subtilis* strain PY79 to 5 mg/liter chloramphenicol resistance, and a double crossover event was confirmed using PCR and the same primers used to clone *yaaDE*. The resulting strain was named PX1.

PX1 was able to grow on Spizizen's minimal medium with trace elements (SMM) (Harwood, C., and Cutting, S. (1990) Molecular Biological Methods for *Bacillus*, John Wiley and Sons, New York, NY, pp. 548-549) supplemented with 2 μM pyridoxal HCl (Sigma-Aldrich Chemical Co.), but it did not grow without the supplement. Thus it was established that at least one of *yaaD* or *yaaE* is required for PLP synthesis in *B. subtilis*.

EXAMPLE 3: Deletion of *yhaF* in *B. subtilis*.

The protein sequence of the *E. coli pdxF* gene was used as a probe to search *the B. subtilis* genome as described in Example 1. The only significant homolog was *yhaF*. In a fashion similar to that of Example 1, the *yhaF* was cloned and deleted from the chromosome of PY79 using plasmid pDX11F (SEQ ID NO:6, Figure 5), to give strain PX11. The PCR primers used to clone *yhaF* were RY407 (SEQ ID NO:3) and RY408 (SEQ ID NO:4). The restriction sites used for insertion of the antibiotic resistance gene were the *PshA1* and *EheI* sites in the *yhaF* coding region. PX11 is a serine auxotroph, but not a PL auxotroph. By comparison to *E. coli*, it appears that *yhaF* functions in serine synthesis and probably encodes the equivalent of *SerC*, but that the YhaF protein is not required for PLP synthesis in *B. subtilis*. Therefore, it is established that sequence homology does not necessarily imply functional homology.

EXAMPLE 4: Overexpression of the *yaaDE* operon in *B. subtilis*.

The *XbaI* to *BamHI* fragment from pAN368 that contains the y*aaDE* operon and artificial ribosome binding site was inserted into either of two expression

vectors, to yield plasmids pDX14R (SEQ ID NO:7) and pDX17R (SEQ ID NO:8), respectively. In pDX14R and pDX17R, the *yaaDE* operon is expressed from the strong constitutive *B. subtilis* phage SP01 promoters, P_{26} and P_{15}, respectively (*see* Figures 6 and 7).

pDX14R and pDX17R were each transformed into wild type *B. subtilis* strain PY79, selecting for chloramphenicol resistance. The plasmids integrate into the chromosome at the *yaaDE* locus by single crossover. The resulting strains were named PX14 and PX17, respectively.

PX14 and PX17 were grown for 48 hours at 37°C in 5 ml test tube cultures in a roller drum at about 100 rotations per minute. The culture medium was SVY (20 g Difco Veal Infusion Broth, 5 g Difco Yeast Extract, 2 g ammonium sulfate, 5 g sodium glutamate, and 30 g glucose per liter, buffered with 200 mM potassium phosphate, pH 7.0). Cells were removed by centrifugation followed by sterile filtration (Millipore 0.45 micron), and the supernatant solutions were assayed for PL equivalents using the biological assay described in Example 1. The parent strain, PY79 was grown and processed in similar fashion as a control. The uncultured SVY medium was assayed as another control, since it was likely that the SVY medium contained a measurable level of B6 vitamers. The results are shown in Table 2, below.

Table 2: Production of B6 vitamers by *Bacillus subtilits* derivatives in 48 hour test tube cultures grown in SVY

Strain	Cassette	Integration Target	OD_{600}	Total B6 Vitamers[1] mg/liter	Net B6 Vitamers[2] mg/liter
PX14	P_{26}*yaaDE*	*yaaDE*	17	7.2	7.0
PX17	P_{15}*yaaDE*	*yaaDE*	17	4.9	4.7
PX1	*ΔyaaDE*	*yaaDE*	8	0.4	0.2
PY79	-	-	19	0.8	0.6
(Medium)	-	-	0.08	0.2	(0)

[1] Sum of PN, PL, PM, and derivatives thereof that can be utilized by pyridoxine indicator strain *S. carlbergensis* as a source of vitamin B6 for growth.

[2] Calculated by subtracting the amount assayed in the medium.

After subtracting the B6 vitamers contained in the medium, strain PX14 produced 7.0 mg/liter PL equivalents, while the parent PY79 produced only 0.6 mg/liter of PL equivalents. Thus, expression of the *yaaDE* operon has been shown to be rate limiting for B6 vitamer production in *B. subtilis*. Moreover, a genetically modified

strain, where this rate limiting step was enhanced, produced more than a ten-fold increase in B6 vitamer secretion compared to that of the parent.

EXAMPLE 5: Complementation of* E. coli pdx *mutants by plasmids that express the* B. subtilis yaaDE *operon.

Plasmid pDX14R, described above in Example 4, was used to transform various *E. coli* strains that contained mutations that lacked function in each of the known genes involved in PLP biosyntehsis (except for *dxs*, which is an essential gene for *E. coli*). The selection was for resistance to 250 mg/liter ampicillin. Each transformant was then tested for growth on minimal medium (SMM with 0.5 % glucose, see Example 2) supplemented with 100 mg/liter serine, and compared to growth of its respective untransformed parent on the same medium. All mutations tested were complemented by pDX14R. Specifically, *pdxA, pdxB, pdxF, pdxJ,* and *pdxH*, were all complemented by pDX14R. Therefore, expression of the *B. subtilis yaaDE* operon in *E. coli* is sufficient for PLP biosynthesis, even in the absence of any one of the above functional *pdx* genes. Several important and unexpected conclusions or inferences can be drawn form these results. First, the substrate(s) for the enzyme(s) encoded by *yaaDE* must be present in *E. coli*, even when a biosynthetic intermediate normally used to make PLP is absent or greatly reduced. Second, PNP or PLP is possibly the product of the enzyme(s) encoded by *yaaDE*. Third, since an early block in the *E. coli* PLP biosynthetic pathway (for example that in a *pdxB* mutant) does not prevent *yaaDE* from complementation, the substrates for the enzyme(s) encoded by *yaaDE* are not likely to be the same as for the last step in PNP or PLP synthesis in wild type *E. coli*. These unexpected results lead to the possibility of producing B6 vitamers using *B. subtilis yaaDE* or the homologous genes from another organism (for example, but not limited to, *SOR* and *SNO* from *Cercospora nicotianae* or *PDX1* and *PDX2* from *S. cerevisiae*) in a heterologous host species, including, but not limited to, *E. coli* and *Oryza sativa*.

EXAMPLE 6: Overexpression of the* yaaDE *operon in E. coli.

Plasmids pDX14R and pDX17R were transformed into *E. coli* strain DH5α (New England Biolabs), selecting for ampicillin resistance. The transformants were grown for 48 hours in 5 ml test tube cultures at 37°C, and the supernatants were worked up as in Example 3. The assay results for PL equivalents are shown in Table 3, below.

Table 3: Production of B6 vitamers by *Escherichia coli* harboring plasmids containing engineered *Bacillus subtilits* genes[1]

Strain	Plasmid Cassette	OD_{600}	Total B6 Vitamers[2] mg/liter	Net B6 Vitamers[3] mg/liter
DH5α	P_{26}*yaaDE*	7.6	3.2	3.1
DH5α	P_{15}*yaaDE*	8.2	3.2	3.1
DH5α	-	9	0.1	(0)

[1] *E. coli* test tube cultures are grown in SVY for 48 hours.
[2] Sum of PN, PL, PM, and derivatives thereof that can be utilized by pyridoxine indicator strain *S. carlbergensis* as a source of vitamin B6 for growth.
[3] Calculated by subtracting the amount assayed in DH5α not containing plasmid.

Thus it has been shown that the *yaaD* and *yaaE* genes can be expressed in a heterologous host strain, and B6 vitamers can still be overproduced. By extension of this approach, the *yaaD* and y*aaE* genes of *B. subtilis* can be overexpressed in any organism where an overexpression system exists, and in the resulting strains, B6 vitamers will be overproduced. Overproduction of the rate limiting enzyme for B6 vitamer production in any organism that is capable of producing B6 vitamers will lead to overproduction of B6 vitamers.

The YaaD and YaaE protein sequences were used as probes to search the NCBI database for homologs in plants using the BLAST™ program which can be found at the National Center for Biotechnology Information website (Altschul S.F (1990) *J. Mol. Biol.* 215(3):403-10). Several homologs of YaaD were found in several genera of plants, including *Arabidopsis, Oryza, Ginkgo, Hevea, Phaseolus,* and *Stellaria.* Two homologs of YaaE were found in *Arabidopsis thaliana.* However, no homologs of *pdxA* and *pdxJ* were found. Therefore the plant kingdom appears to use the Type B Pathway for B6 vitamer biosynthesis. Thus for example, overexpression of the YaaD homolog (GenBank accession number AAL73561) from *Oryza sativa* (rice), and the *A. thaliana* homolog of YaaE (GenBank accession number AB011483) together in a plant using methods well know in the art, such as expression from the Cauliflower Mosaic Virus 35S promoter, will lead to overproduction of B6 vitamers in that plant.

EXAMPLE 7: Other routes to increasing the activity of enzymes involved in B6 vitamer synthesis.

The overexpression of the *yaaDE* operon leads to an increase in the amount of the encoded enzyme(s), which in turn leads to an increase in the total activity of said enzyme(s). Increase in this activity leads to an increase in the production B6 vitamer. Other methods can be used to increase the activity of the relevant enzyme(s)

under conditions of B6 vitamer production. For example, in addition to increasing the amount of a relevant enzyme(s), the total activity of the relevant enzyme(s) can be increased by mutating the gene(s) to increase the specific activity of the enzyme(s), and/or by mutating the gene(s) to encode a feedback resistant variant of the enzyme(s). Such desirable mutations can be obtained by screening large numbers of mutants for the increased activity as evidenced by an increase in B6 vitamer production as described in Example 4, or by selecting for mutants that are resistant to inhibitors that are specific for the PLP biosynthetic pathway, and screening among those mutants for an increase in B6 vitamer production. Examples of such inhibitors are isoniazid, iproniazid, and ginkgotoxin (4'-methoxy pyridoxine) (Dempsey and Arcement (1971) J. Bacteriol. 107(2): 580-582; Pflug, W., and Lingens, F., (1978) Hoppe-Seyler's Z. Physiol. Chem. 359: 559-570; Fiehe, K., et al., (2000) J. Nat. Prod. 63(2): 185-189).

EXAMPLE 8: Processing of biosynthetic B6 vitamers.

A B6 vitamer produced by a genetically modified organism of the invention can be harvested and processed into a format that is appropriate for commercial use. For example, after culturing a B6 vitamer producing micro-organism in liquid culture, the entire culture, including cells can be dried by evaporation or by spray drying, and the resulting powder can be mixed into animal feeds. Alternatively, the cells can be first removed by centrifugation or filtration, and the resulting supernatant solution can be dried as described above. As another alternative, the B6 vitamer can be purified from the culture broth by techniques well known in the art, such as filtration, reverse osmosis, column chromatography (ion exchange, hydrophobic or hyrophilic adsorption, gel filtration, etc.), solvent extraction, precipitation, distillation, evaporation, and the like. If the B6 vitamer producing organism is a plant, then the appropriate portion of the plant (for example the leaves, stems, roots, flowers, fruits, seeds, or any combination thereof) can be harvested and processed. For example the plant material can be dried and used directly, or the material can be pulverized or ground and the B6 vitamer extracted and/or processed as described above for cultures.

The production organism can be a micro-organism that normally inhabits the gut of humans or an animal if interest (for example one of many bacteria of the genus *Lactobacillus,* such as *L. acidophilus*), and the B6 vitamer can be delivered by ingestion of the organism.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

Claims

5

What is claimed:

1. An organism that has been genetically modified to comprise a recombinant DNA molecule that results in the increase of the activity of one or more enzymes that catalyze(s) a step in the biosynthesis of a B6 vitamer, such that B6 vitamer production from said modified organism is increased compared to B6 production in an unmodified parent organism.

2. The organism of claim 1, wherein B6 vitamer production is at least ten-fold higher than from the unmodified parent organism.

3. The organism of claim 1, wherein said enzyme is one or more of YaaD or YaaE.

4. The organism of claim 1, wherein said organism is genetically modified to overexpress one or more genes that encodes an enzyme that catalyzes a step in the biosynthesis of a B6 vitamer.

5. The organism of claim 4, wherein at least one of said genes is a *yaaD* gene.

6. The organism of claim 4, wherein at least one of said genes is a *yaaE* gene.

7. The organism of claim 4, wherein at least two of said genes are *yaaD* and *yaaE* genes.

8. The organism of claim 4, wherein said organism is a *Bacillus* strain.

9. The organism of claim 4, wherein said organism is *Bacillus subtilis*.

10. The organism of claim 4, wherein said organism is *Escherichia coli*.

11. The organism of claim 10, wherein said genes are selected from the group consisting of *E. coli epd, pdxA, pdxJ, pdxF, pdxB, pdxH* or *dxs*.

12. The organism of any one of claims 1-11, wherein said organism is grown in a liquid culture and the total B6 vitamer concentration in the culture supernatant it at least 7.0 mg/liter.

13. A method of producing a B6 vitamer comprising culturing a microorganism that has been genetically modified to overexpress one or more genes that encodes an enzyme that catalyzes a step in the biosynthesis of a B6 vitamer, such that B6 vitamer production from said modified organism is increased compared to B6 production in an unmodified parent organism, under conditions such that the B6 vitamer is produced.

14. The method of claim 13, wherein said enzyme is one or more of YaaD or YaaE.

15. The method of claim 13, wherein at least one of said genes is a *yaaD* gene.

16. The method of claim 13, wherein at least one of said genes is a *yaaE* gene.

17. The method of claim 13, wherein said genes are contained on the *yaaDE* operon.

18. The method of claim 13, wherein the B6 vitamer is pyridoxine.

19. The method of claim 13, wherein the B6 vitamer is pyridoxal.

20. The method of claim 13, wherein the B6 vitamer is pyridoxamine.

21. The method of claim 13, wherein the said genes are bacterial-derived.

22. The method of claim 13, wherein said genes are derived from *Bacillus*.

23. The method of claim 13, wherein said genes are derived from *Bacillus subtilis*.

24. The method of claim 13, wherein the microorganism is Gram positive.

25. The method of claim 13, wherein the microorganism is a microorganism belonging to a genus selected from the group consisting of *Bacillus*, *Cornyebacterium*, *Lactobacillus*, *Lactococci* and *Streptomyces*.

26. The method of claim 13, wherein the microorganism is of the genus *Bacillus*.

27. The method of claim 13, wherein the microorganism is *Bacillus subtilis*.

28. The method of claim 13, further comprising recovering the B6 vitamer.

29. A method of producing a B6 vitamer comprising culturing a microorganism that overexpresses at least one *Bacillus* B6 vitamer biosynthetic gene under conditions such that the B6 vitamer is produced.

30. The method of claim 29, wherein the microorganism overexpresses at least one *Bacillus subtilis* B6 vitamer biosynthetic enzyme.

31. The method of claim 29, wherein the B6 vitamer is pyridoxine.

32. The method of claim 29, wherein the B6 vitamer is pyridoxal.

33. The method of claim 29, wherein the B6 vitamer is pyridoxamine.

34. The method of claim 29, wherein the microorganism overexpresses at least two B6 vitamer biosynthetic enzymes.

35. The method of claim 29, wherein the microorganism is Gram positive.

36. The method of claim 29, wherein the microorganism is Gram negative.

37. The method of claim 29, wherein the microorganism is a microorganism belonging to a genus selected from the group consisting of *Bacillus*, *Cornyebacterium*, *Lactobacillus*, *Lactococci* and *Streptomyces*.

38. The method of claim 29, wherein the microorganism is of the genus *Bacillus*.

39. The method of claim 29, wherein the microorganism is *Bacillus subtilis*.

40. The method of claim 29, further comprising recovering the B6 vitamer.

41. A recombinant microorganism that overexpresses at least one *Bacillus* B6 vitamer biosynthetic gene.

42. A recombinant microorganism that overexpresses at least one *Bacillus* B6 vitamer biosynthetic enzyme.

43. The method of claim 42, wherein said enzyme is YaaD or YaaE.

44. The recombinant microorganism of claim 41 that overexpresses at least one *Bacillus subtilis* B6 vitamer biosynthetic gene.

45. The recombinant microorganism of claim 41, wherein the B6 vitamer biosynthetic gene is selected from the group consisting of *yaaD* and *yaaE*.

46. The recombinant microorganism of claim 41, that is Gram positive.

47. The recombinant microorganism of claim 41 belonging to a genus selected from the group consisting of *Bacillus*, *Cornyebacterium*, *Lactobacillus*, *Lactococci* and *Streptomyces*.

48. The recombinant microorganism of claim 41 belonging to the genus *Bacillus*.

49. The recombinant microorganism of claim 41 which is *Bacillus subtilis*.

50. A recombinant microorganism selected from the group consisting of PX14 and PX17.

51. A vector comprising a nucleic acid sequence that encodes at least one *Bacillus* B6 vitamer biosynthetic gene operably linked to regulatory sequences.

52. The vector of claim 51, comprising a nucleic acid sequence that encodes at least one *Bacillus subtilis* B6 vitamer biosynthetic gene.

53. The vector of claim 51, wherein the regulatory sequences comprise a constitutively active promoter.

54. The vector of claim 51, wherein the constitutively active promoter comprises P_{15} (SEQ ID NO:9) or P_{26} (SEQ ID NO:10) sequences.

55. The vector of claim 51, wherein the regulatory sequences comprise at least one artificial ribosome binding site (RBS).

56. A vector selected from the group consisting of pDX14R and pDX17R.

57. A recombinant microorganism comprising the vector of claim 56.

58. An isolated nucleic acid molecule that encodes at least one *Bacillus* B6 vitamer biosynthetic gene.

59. The isolated nucleic acid molecule of claim 58 that encodes at least one *Bacillus subtilis* B6 vitamer biosynthetic gene.

60. An isolated *Bacillus* B6 vitamer biosynthetic enzyme polypeptide.

61. An isolated *Bacillus subtilis* B6 vitamer biosynthetic enzyme polypeptide.

METHODS AND ORGANISMS FOR PRODUCTION OF B6 VITAMERS

Abstract of the Disclosure

The present invention features methods of producing B6 vitamers that involve culturing an organism overexpressing an enzyme that catalyzes a step in the biosynthesis of a B6 vitamer under conditions such that a B6 vitamer is produced. The present invention further features methods of producing B6 vitamers that involve culturing recombinant microorganisms that overexpress at least one B6 vitamer biosynthetic gene, *e.g.*, *yaaD* or *yaaE*.

Figure 1



pyridoxol



pyridoxal



pyridoxamine



pyridoxol phosphate



pyridoxal phosphate



pyridoxamine phosphate

Figure 2



Figure 3



Figure 4. Structure of pDX1F



Figure 5. Structure of pDX11F



Figure 6


pDX14R
6.8Kb
cat
amp
'tet
P26
T1, T2
yaaE
yaaD
from pBR322
1.0 Kb
2.0 Kb
3.0 Kb
4.0 Kb
5.0 Kb
6.0 Kb
Not I
Aat II
Ase I
Nco I
EcoR I
Acc65 I
Kpn I
BamH I
Pvu II
Ase I
EcoR I
Cla I
Pvu II
Sph I
Hpa I
Ase I
Pvu II
Hpa I
Hind III
Avr II
Hpa I
Nde I
Aat II
Xba I
EcoR V
Ava I
Xho I
Sal I
Pst I
Sph I
Hind III
Not I
Ava I
Pvu II
Nde I
Ase I
Pst I
Pvu I

FIGURE 7. *Structure of pDX17R*



SEQUENCE LISTING

<110> Yocum, R. Rogers
Williams, Mark K.
Pero, Janice G.

<120> METHODS AND ORGANISMS FOR PRODUCTION OF B6 VITAMERS

<130> BGI-152-1

<160> 19

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 1
ccctctagag gaggagaaaa catggctcaa acaggtactg aacgtg 46

<210> 2
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 2
cccggatcct caactgtttt atacaagtgc cttttgctta tattc 45

<210> 3
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 3
ccctctagag gaggagacat aatggaacgt acaacgaatt ttaacgcag 49

<210> 4
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 4
cccggatccc ggacggtttg catagccaga ctttttactc a 41

<210> 5
<211> 5322
<212> DNA

<213> Artificial Sequence

<220>
<223> plasmid - pDX1F

<400> 5
tgcgccgcta cagggcgcgt ccattcgcca ttcaggctgc gcaactgttg ggaagggcga 60
tcggtgcggg cctcttcgct attacgccag ctggcgaaag ggggatgtgc tgcaaggcga 120
ttaagttggg taacgccagg gttttcccag tcacgacgtt gtaaaacgac ggccagtgaa 180
ttgtaatacg actcactata gggcgaattg ggcccgacgt cgcatgctcc cggccgccat 240
ggccgcggga tccctctaga ggaggagaaa acatggctca aacaggtact gaacgtgtaa 300
aacgcggaat ggcagaaatg caaaaaggcg gcgtcatcat ggacgtcatc aatgcggaac 360
aagcgaaaat cgctgaagaa gctggagctg tcgctgtaat ggcgctagaa cgtgtgccag 420
cagatattcg cgcggctgga ggagttgccc gtatggctga ccctacaatc gtggaagaag 480
taatgaatgc agtatctatc ccggtaatgg caaaagcgcg tatcggacat attgttgaag 540
cgcgtgtgct tgaagctatg ggtgttgact atattgatga aagtgaagtt ctgacgccgg 600
ctgacgaaga atttcattta aataaaaatg aatacacagt tccttttgtc tgtggctgcc 660
gtgatcttgg tgaagcaaca cgccgtattg cggaaggtgc ttctatgctt cgcacaaaag 720
gtgagcctgg aacaggtaat attgttgagg ctgttcgcca tatgcgtaaa gttatcacta 780
gtgcggccgc ctgcaggtcg accatatggg agaggcggcc gcgtcgacca atagttaccc 840
ttattatcaa gataagaaag aaaaggattt ttcgctacgc tcaaatcctt taaaaaaaca 900
caaaagacca catttttttaa tgtggtcttt attcttcaac taaagcaccc attagttcaa 960
caaacgaaaa ttggataaag tgggatattt ttaaaatata tatttatgtt acagtaatat 1020
tgacttttaa aaaaggattg attctaatga agaaagcaga caagtaagcc tcctaaattc 1080
actttagata aaaatttagg aggcatatca aatgaacttt aataaaattg atttagacaa 1140
ttggaagaga aaagagatat ttaatcatta tttgaaccaa caaacgactt ttagtataac 1200
cacagaaatt gatattagtg ttttataccg aaacataaaa caagaaggat ataaatttta 1260
ccctgcattt attttcttag tgacaagggt gataaactca aatacagctt ttagaactgg 1320
ttacaatagc gacggagagt taggttattg ggataagtta gagccacttt atacaatttt 1380
tgatggtgta tctaaaacat tctctggtat ttggactcct gtaaagaatg acttcaaaga 1440
gttttatgat ttatacettt ctgatgtaga gaaatataat ggttcgggga aattgtttcc 1500
caaaacacct atacctgaaa atgctttttc tctttctatt attccatgga cttcatttac 1560
tgggtttaac ttaaatatca ataataatag taattacctt ctacccatta ttacagcagg 1620
aaaattcatt aataaaggta attcaatata tttaccgcta tctttacagg tacatcattc 1680
tgtttgtgat ggttatcatg caggattgtt tatgaactct attcaggaat tgtcagatag 1740
gcctaatgac tggcttttat aatatgagat aatgccgact gtacttttta cagtcggttt 1800
tctaatgtca ctaacctgcc ccgttagttg aagaaggttt ttatattaca gctccggtac 1860
cgggctccca acgcgttgga tgcatagctt gagtattcta tagtgtcacc taaatagctt 1920
ggcgtaatca tggtcatagc tgtttcctgt gtgaaattgt tatccgaaca ataggtgtac 1980
taggacttca aggagcagtt agagagcaca tccatgcgat tgaagcatgc ggcgcggctg 2040
gtcttgtcgt aaaacgtccg gagcagctga acgaagttga cgggttgatt ttgccgggcg 2100
gtgagagcac gacgatgcgc cgtttgatcg atacgtatca attcatggag ccgcttcgtg 2160
aattcgctgc tcagggcaaa ccgatgtttg gaacatgtgc cggattaatt atattagcaa 2220
aagaaattgc cggttcagat aatcctcatt taggtcttct gaatgtggtt gtagaacgta 2280
attcatttgg ccggcaggtt gacagctttg aagctgattt aacaattaaa ggcttggacg 2340
agccttttac tggggtattc atccgtgctc cgcatatttt agaagctggt gaaaatgttg 2400
aagttctatc ggagcataat ggtcgtattg tagccgcgaa acaggggcaa ttccttggct 2460
gctcattcca tccggagctg acagaagatc accgagtgac gcagctgttt gttgaaatgg 2520
ttgaggaata taagcaaaag gcacttgtat aaaacagttg aggatccggg atcactagtg 2580
cggccgcctg caggtcgacc atatgggaga gctcccaacg cgttggatgc atagcttgag 2640
tattctatag tgtcacctaa atagcttggc gtaatcatgg tcatagctgt ttcctgtgtg 2700
aaattgttat ccgctcacaa ttccacacaa catacgagcc ggaagcataa agtgtaaagc 2760
ctggggtgcc taatgagtga gctaactcac attaattgcg ttgcgctcac tgcccgcttt 2820
ccagtcggga aacctgtcgt gccagctgca ttaatgaatc ggccaacgcg cggggagagg 2880
cggtttgcgt attgggcgct cttccgcttc ctcgctcact gactcgctgc gctcggtcgt 2940
tcggctgcgg cgagcggtat cagctcactc aaaggcggta atacggttat ccacagaatc 3000
aggggataac gcaggaaaga acatgtgagc aaaaggccag caaaaggcca ggaaccgtaa 3060
aaaggccgcg ttgctggcgt ttttcgatag gctccgcccc cctgacgagc atcacaaaaa 3120
tcgacgctca agtcagaggt ggcgaaaccc gacaggacta taaagatacc aggcgtttcc 3180
ccctggaagc tccctcgtgc gctctcctgt tccgaccctg ccgcttaccg gatacctgtc 3240
cgcctttctc ccttcgggaa gcgtggcgct ttctcatagc tcacgctgta ggtatctcag 3300

ttcggtgtag gtcgttcgct ccaagctggg ctgtgtgcac gaaccccccg ttcagcccga 3360
ccgctgcgcc ttatccggta actatcgtct tgagtccaac ccggtaagac acgacttatc 3420
gccactggca gcagccactg gtaacaggat tagcagagcg aggtatgtag gcggtgctac 3480
agagttcttg aagtggtggc ctaactacgg ctacactaga aggacagtat ttggtatctg 3540
cgctctgctg aagccagtta ccttcggaaa aagagttggt agctcttgat ccggcaaaca 3600
aaccaccgct ggtagcggtg gtttttttgt ttgcaagcag cagattacgc gcagaaaaaa 3660
aggatctcaa gaagatcctt tgatcttttc tacggggtct gacgctcagt ggaacgaaaa 3720
ctcacgttaa gggattttgg tcatgagatt atcaaaaagg atcttcacct agatcctttt 3780
aaattaaaaa tgaagtttta aatcaatcta aagtatatat gagtaaactt ggtctgacag 3840
ttaccaatgc ttaatcagtg aggcacctat ctcagcgatc tgtctatttc gttcatccat 3900
agttgcctga ctccccgtcg tgtagataac tacgatacgg gagggcttac catctggccc 3960
cagtgctgca atgataccgc gagacccacg ctcaccggct ccagatttat cagcaataaa 4020
ccagccagcc ggaagggccg agcgcagaag tggtcctgca actttatccg cctccatcca 4080
gtctattaat tgttgccggg aagctagagt aagtagttcg ccagttaata gtttgcgcaa 4140
cgttgttggc attgctacag gcatcgtggt gtcacgctcg tcgtttggta tggcttcatt 4200
cagctccggt tcccaacgat caaggcgagt tacatgatcc cccatgttgt gcaaaaaagc 4260
ggttagctcc ttcggtcctc cgatcgttgt cagaagtaag ttggccgcag tgttatcact 4320
catggttatg gcagcactgc ataattctct tactgtcatg ccatccgtaa gatgcttttc 4380
tgtgactggt gagtactcaa ccaagtcatt ctgagaatac cgcgcccggc gaccgagttg 4440
ctcttgcccg gcgtcaatac gggataatag tgtatgacat agcagaactt taaaagtgct 4500
catcattgga aaacgttctt cggggcgaaa actctcaagg atcttaccgc tgttgagatc 4560
cagttcgatg taacccactc gtgcacccaa ctgatcttca gcatctttta ctttcaccag 4620
cgtttctggg tgagcaaaaa caggaaggca aaatgccgca aaaaagggaa taagggcgac 4680
acggaaatgt tgaatactca tactcttcct ttttcaatat tattgaagca tttatcaggg 4740
ttattgtctc atgagcggat acatatttga atgtatttag aaaaataaac aaataggggt 4800
tccgcgcaca tttccccgaa aagtgccacc tgtatgcggt gtgaaatacc gcacagatgc 4860
gtaaggagaa aataccgcat caggcgaaat tgtaaacgtt aatattttgt taaaattcgc 4920
gttaaatatt tgttaaatca gctcattttt taaccaatag gccgaaatcg gcaaaatccc 4980
ttataaatca aaagaataga ccgagatagg gttgagtgtt gttccagttt ggaacaagag 5040
tccactatta aagaacgtgg actccaacgt caaagggcga aaaaccgtct atcagggcga 5100
tggcccacta cgtgaaccat cacccaaatc aagttttttg cggtcgaggt gccgtaaagc 5160
tctaaatcgg aaccctaaag ggagcccccg atttagagct tgacggggaa agccggcgaa 5220
cgtggcgaga aaggaaggga agaaagcgaa aggagcgggc gctagggcgc tggcaagtgt 5280
agcggtcacg ctgcgcgtaa ccaccacacc cgcccgcgctt aa 5322

<210> 6
<211> 5297
<212> DNA
<213> Artificial Sequence

<220>
<223> plasmid - pDX11F

<400> 6
tgcgccgcta cagggcgcgt ccattcgcca ttcaggctgc gcaactgttg ggaagggcga 60
tcggtgcggg cctcttcgct attacgccag ctggcgaaag ggggatgtgc tgcaaggcga 120
ttaagttggg taacgccagg gttttcccag tcacgacgtt gtaaaacgac ggccagtgaa 180
ttgtaatacg actcactata gggcgaattg ggcccgacgt cgcatgctcc cggccgccat 240
ggccgcggga tccctctaga ggaggagaca taatggaacg tacaacgaat tttaacgcag 300
gtcctgcagc gctgccactg gaagttctgc aaaaagcaca gaaagaattt attgatttta 360
acgaatccgg catgtctgtt atggagcttt cccaccgcag caaagagtat gaagcggtgc 420
accaaaaagc gaaaagcctc ttaatcgaac tgatgggcat tccggaagat tacgatatct 480
tgtttcttca aggcggggca agccttcaat tctcaatgct tccgatgaac tttttaacac 540
ctgaaaaaac cgcacatttt gtgatgaccg gcgcttggtc tgaaaaagca ctggcagaaa 600
cgaaactgtt cgggaacacg tctatcaccg ctacaagtga aacagacaat tacagttata 660
ttccagaggt tgaccttacg gatgtaaaag acggcgcata tttacatatc acatccaaca 720
atacaatttt cggcactcag tggcaggagt ttccgaattc tccaattccg ctcgtagccg 780
acatgtccag cgatatttta agcagaaaaa tcgatgtgtc caaatttgat gtgatctacg 840
gaggcatcac tagtgcggcc gcctgcaggt cgaccatatg ggagaggcgg ccgcgtcgac 900

```
caatagttac ccttattatc aagataagaa agaaaaggat ttttcgctac gctcaaatcc 960
tttaaaaaaa cacaaaagac cacatttttt aatgtggtct ttattcttca actaaagcac 1020
ccattagttc aacaaacgaa aattggataa agtgggatat ttttaaaata tatatttatg 1080
ttacagtaat attgactttt aaaaaaggat tgattctaat gaagaaagca gacaagtaag 1140
cctcctaaat tcactttaga taaaaattta ggaggcatat caaatgaact ttaataaaat 1200
tgatttagac aattggaaga gaaaagagat atttaatcat tatttgaacc aacaaacgac 1260
ttttagtata accacagaaa ttgatattag tgttttatac cgaaacataa aacaagaagg 1320
atataaattt taccctgcat ttattttctt agtgacaagg gtgataaact caaatacagc 1380
ttttagaact ggttacaata gcgacggaga gttaggttat tgggataagt tagagccact 1440
ttatacaatt tttgatggtg tatctaaaac attctctggt atttggactc ctgtaaagaa 1500
tgacttcaaa gagttttatg atttatacct ttctgatgta gagaaatata atggttcggg 1560
gaaattgttt cccaaaacac ctatacctga aaatgctttt tctctttcta ttattccatg 1620
gacttcattt actgggttta acttaaatat caataataat agtaattacc ttctacccat 1680
tattacagca ggaaaattca ttaataaagg taattcaata tatttaccgc tatctttaca 1740
ggtacatcat tctgtttgtg atggttatca tgcaggattg tttatgaact ctattcagga 1800
attgtcagat aggcctaatg actggctttt ataatatgag ataatgccga ctgtactttt 1860
tacagtcggt tttctaatgt cactaacctg ccccgttagt tgaagaaggt ttttatatta 1920
cagctccggt accgggctcc caacgcgttg gatgcatagc ttgagtattc tatagtgtca 1980
cctaaatagc ttggcgtaat catggtcata gctgtttcct gtgtgaaatt gttatccgta 2040
gtcatcatga aaaaaagctg gctgcaaaat gaaaatgcga acgtcccaaa aatcttgaaa 2100
tattccacgc atgtcaaagc ggattcactc tacaacactc cgccgacatt tgcgatttat 2160
atgctgagcc tcgttctgga atggctcaag gaaaacggcg gtgtggaagc tgttgaacag 2220
cgcaatgaac aaaaagcgca ggttctctac agctgtattg atgaaagcaa cggcttctat 2280
aaaggacatg ccagaaaaga cagccgctca cgcatgaatg tcacattcac gcttcgggat 2340
gacgaattaa cgaaaacatt cgttcagaaa gcaaaagatg cgaagatgat cggccttggc 2400
ggacaccgtt cggtgggagg ctgccgcgct tctatttata acgcggtctc tctcgaagac 2460
tgtgaaaaat tagctgcgtt catgaagaaa ttccagcagg aaaatgagta aaaagtctgg 2520
ctatgcattc cgtccgggat ccgggatcac tagtgcggcc gcctgcaggt cgaccatatg 2580
ggagagctcc caacgcgttg gatgcatagc ttgagtattc tatagtgtca cctaaatagc 2640
ttggcgtaat catggtcata gctgtttcct gtgtgaaatt gttatccgct cacaattcca 2700
cacaacatac gagccggaag cataaagtgt aaagcctggg gtgcctaatg agtgagctaa 2760
ctcacattaa ttgcgttgcg ctcactgccc gctttccagt cgggaaacct gtcgtgccag 2820
ctgcattaat gaatcggcca acgcgcgggg agaggcggtt tgcgtattgg gcgctcttcc 2880
gcttcctcgc tcactgactc gctgcgctcg gtcgttcggc tgcggcgagc ggtatcagct 2940
cactcaaagg cggtaatacg gttatccaca gaatcagggg ataacgcagg aaagaacatg 3000
tgagcaaaag gccagcaaaa ggccaggaac cgtaaaaagg ccgcgttgct ggcgtttttc 3060
gataggctcc gcccccctga cgagcatcac aaaaatcgac gctcaagtca gaggtggcga 3120
aacccgacag gactataaag ataccaggcg tttccccctg gaagctccct cgtgcgctct 3180
cctgttccga ccctgccgct taccggatac ctgtccgcct ttctcccttc gggaagcgtg 3240
gcgctttctc atagctcacg ctgtaggtat ctcagttcgg tgtaggtcgt tcgctccaag 3300
ctgggctgtg tgcacgaacc ccccgttcag cccgaccgct gcgccttatc cggtaactat 3360
cgtcttgagt ccaacccggt aagacacgac ttatcgccac tggcagcagc cactggtaac 3420
aggattagca gagcgaggta tgtaggcggt gctacagagt tcttgaagtg gtggcctaac 3480
tacggctaca ctagaaggac agtatttggt atctgcgctc tgctgaagcc agttaccttc 3540
ggaaaaagag ttggtagctc ttgatccggc aaacaaacca ccgctggtag cggtggtttt 3600
tttgtttgca agcagcagat tacgcgcaga aaaaaaggat ctcaagaaga tcctttgatc 3660
ttttctacgg ggtctgacgc tcagtggaac gaaaactcac gttaagggat tttggtcatg 3720
agattatcaa aaaggatctt cacctagatc cttttaaatt aaaaatgaag ttttaaatca 3780
atctaaagta tatatgagta aacttggtct gacagttacc aatgcttaat cagtgaggca 3840
cctatctcag cgatctgtct atttcgttca tccatagttg cctgactccc cgtcgtgtag 3900
ataactacga tacgggaggg cttaccatct ggccccagtg ctgcaatgat accgcgagac 3960
ccacgctcac cggctccaga tttatcagca ataaaccagc cagccggaag ggccgagcgc 4020
agaagtggtc ctgcaacttt atccgcctcc atccagtcta ttaattgttg ccgggaagct 4080
agagtaagta gttcgccagt taatagtttg cgcaacgttg ttggcattgc tacaggcatc 4140
gtggtgtcac gctcgtcgtt tggtatggct tcattcagct ccggttccca acgatcaagg 4200
cgagttacat gatcccccat gttgtgcaaa aaagcggtta gctccttcgg tcctccgatc 4260
gttgtcagaa gtaagttggc cgcagtgtta tcactcatgg ttatggcagc actgcataat 4320
tctcttactg tcatgccatc cgtaagatgc ttttctgtga ctggtgagta ctcaaccaag 4380
tcattctgag aataccgcgc ccggcgaccg agttgctctt gcccggcgtc aatacgggat 4440
aatagtgtat gacatagcag aactttaaaa gtgctcatca ttggaaaacg ttcttcgggg 4500
cgaaaactct caaggatctt accgctgttg agatccagtt cgatgtaacc cactcgtgca 4560
```

cccaactgat cttcagcatc ttttactttc accagcgttt ctgggtgagc aaaaacagga 4620
aggcaaaatg ccgcaaaaaa gggaataagg gcgacacgga aatgttgaat actcatactc 4680
ttccttttc aatattattg aagcatttat cagggttatt gtctcatgag cggatacata 4740
tttgaatgta tttagaaaaa taaacaaata ggggttccgc gcacatttcc ccgaaaagtg 4800
ccacctgtat gcggtgtgaa ataccgcaca gatgcgtaag gagaaaatac cgcatcaggc 4860
gaaattgtaa acgttaatat tttgttaaaa ttcgcgttaa atatttgtta aatcagctca 4920
ttttttaacc aataggccga aatcggcaaa atcccttata aatcaaaaga atagaccgag 4980
atagggttga gtgttgttcc agtttggaac aagagtccac tattaaagaa cgtggactcc 5040
aacgtcaaag ggcgaaaaac cgtctatcag ggcgatggcc cactacgtga accatcaccc 5100
aaatcaagtt ttttgcggtc gaggtgccgt aaagctctaa atcggaaccc taaagggagc 5160
ccccgattta gagcttgacg gggaaagccg gcgaacgtgg cgagaaagga agggaagaaa 5220
gcgaaaggag cgggcgctag ggcgctggca agtgtagcgg tcacgctgcg cgtaaccacc 5280
acacccgccg cgcttaa 5297

<210> 7
<211> 6731
<212> DNA
<213> Artificial Sequence

<220>
<223> plasmid - pDX14R

<400> 7
ttgcggccgc ttcgaaagct gtaatataaa aaccttcttc aactaacggg gcaggttagt 60
gacattagaa aaccgactgt aaaaagtaca gtcggcatta tctcatatta taaaagccag 120
tcattaggcc tatctgacaa ttcctgaata gagttcataa acaatcctgc atgataacca 180
tcacaaacag aatgatgtac ctgtaaagat agcggtaaat atattgaatt acctttatta 240
atgaattttc ctgctgtaat aatgggtaga aggtaattac tattattatt gatatttaag 300
ttaaacccag taaatgaagt ccatggaata atagaaagag aaaaagcatt ttcaggtata 360
ggtgttttgg gaaacaattt ccccgaacca ttatatttct ctacatcaga aaggtataaa 420
tcataaaact ctttgaagtc attctttaca ggagtccaaa taccagagaa tgttttagat 480
acaccatcaa aaattgtata aagtggctct aacttatccc aataacctaa ctctccgtcg 540
ctattgtaac cagttctaaa agctgtattt gagtttatca cccttgtcac taagaaaata 600
aatgcagggt aaaatttata tccttcttgt tttatgtttc ggtataaaac actaatatca 660
atttctgtgg ttatactaaa agtcgtttgt tggttcaaat aatgattaaa tatctctttt 720
ctcttccaat tgtctaaatc aattttatta aagttcattt gatatgcctc ctaaattttt 780
atctaaagtg aatttaggag gcttacttgt ctgctttctt cattagaatc aatccttttt 840
taaaagtcaa tattactgta acataaatat atattttaaa aatatcccac tttatccaat 900
tttcgtttgt tgaactaatg ggtgctttag ttgaagaata aagaccacat taaaaaatgt 960
ggtcttttgt gtttttttaa aggatttgag cgtagcgaaa aatccttttc tttcttatct 1020
tgataataag ggtaactatt gaattcggta ccaagagttt gtagaaacgc aaaaaggcca 1080
tccgtcagga tggccttctg cttaatttga tgcctggcag tttatggcgg gcgtcctgcc 1140
cgccaccctc cgggccgttg cttcgcaacg ttcaaatccg ctcccggcgg atttgtccta 1200
ctcaggagag cgttcaccga caaacaacag ataaaacgaa aggcccagtc tttcgactga 1260
gcctttcgtt ttatttgatg cctggcagtt ccctactctc gcatggggag accccacact 1320
accatcggcg ctacggcgtt tcacttctga gttcggcatg gggtcaggtg ggaccaccgc 1380
gctactgccg ccaggcaaat tctgttttat cagaccgctt ctgcgttctg atttaatctg 1440
tatcaggctg aaaatcttct ctcatccgcc aaaacaggat cctcaactgt tttatacaag 1500
tgccttttgc ttatattcct caaccatttc aacaaacagc tgcgtcactc ggtgatcttc 1560
tgtcagctcc ggatggaatg agcagccaag gaattgcccc tgtttcgcgg ctacaatacg 1620
accattatgc tccgatagaa cttcaacatt ttcaccagct tctaaaatat gcggagcacg 1680
gatgaatacc ccagtaaaag gctcgtccaa gcctttaatt gttaaatcag cttcaaagct 1740
gtcaacctgc cggccaaatg aattacgttc tacaaccaca ttcagaagac ctaaatgagg 1800
attatctgaa ccggcaattt cttttgctaa tataattaat ccggcacatg ttccaaacat 1860
cggtttgccc tgagcagcga attcacgaag cggctccatg aattgatacg tatcgatcaa 1920
acggcgcatc gtcgtgctct caccgcccgg caaaatcaac ccgtcaactt cgttcagctg 1980
ctccggacgt tttacgacaa gaccagccgc gccgcatgct tcaatcgcat ggatgtgctc 2040
tctaactgct ccttgaagtc ctagtacacc tattgttaac atgtcagcag cgctcctatg 2100
ttcttaccag ccgcgttctt gcatacgctg ttctggaagt aagtttgaga tttcaatccc 2160

tttcattgca gtaccaagct cttttgacaa ctcagcgatt aatttgtaat cagtaaagtg 2220
agttgttgct tccacaattg ctttcgcaaa tttagcaggg ttgtctgatt taaaaatacc 2280
agaaccaaca aatactccgt cagcaccaag ctgcatcatg agagcagcat cagctggagt 2340
tgctacgccg ccagcggcaa agttaacgac aggaagcttg ccgtcttttt taatttgaag 2400
aagaagctcg taaggagcac ctaggttttt cgcttctgtc attagctcat cctcactcat 2460
cgcaactact ttgcgcactt gagcgttaac tttacgcata tggcgaacag cctcaacaat 2520
attacctgtt ccaggctcac cttttgtgcg aagcatagaa gcaccttccg caatacggcg 2580
tgttgcttca ccaagatcac ggcagccaca gacaaaagga actgtgtatt catttttatt 2640
taaatgaaat tcttcgtcag ccggcgtcag aacttcactt tcatcaatat agtcaacacc 2700
catagcttca agcacacgcg cttcaacaat atgtccgata cgcgcttttg ccattaccgg 2760
gatagatact gcattcatta cttcttccac gattgtaggg tcagccatac gggcaactcc 2820
tccagccgcg cgaatatctg ctggcacacg ttctagcgcc attacagcga cagctccagc 2880
ttcttcagcg attttcgctt gttccgcatt gatgacgtcc atgatgacgc cgcctttttg 2940
catttctgcc attccgcgtt ttacacgttc agtacctgtt tgagccatgt tttctcctcc 3000
tctagagcgt cctgctgttg ttaagattat tataccacac cttgtagata aagtcaacaa 3060
ctttttgcaa aatttttcag gaattttagc agaggttgtt ctggatgtag aacaaaacat 3120
ctttccgctc ttgtgctgtt aggatatctt tcttggaagc taggtaggcc tcgagttatg 3180
gcagttggtt aaaaggaaac aaaaagaccg ttttcacaca aaacggtctt tttcgatttc 3240
tttttacagt cacagccact tttgcaaaaa ccggacagct tcatgcctta taactgctgt 3300
ttcggtcgac ctgcaggcat gcaagcttcg cgaagcggcc gccgacgcga ggctggatgg 3360
ccttccccat tatgattctt ctcgcttccg gcggcatcgg gatgcccgcg ttgcaggcca 3420
tgctgtccag gcaggtagat gacgaccatc agggacagct tcaaggatcg ctcgcggctc 3480
ttaccagcct aacttcgatc actggaccgc tgatcgtcac ggcgatttat gccgcctcgg 3540
cgagcacatg gaacgggttg gcatggattg taggcgccgc cctatacctt gtctgcctcc 3600
ccgcgttgcg tcgcggtgca tggagccggg ccacctcgac ctgaatggaa gccggcggca 3660
cctcgctaac ggattcacca ctccaagaat tggagccaat caattcttgc ggagaactgt 3720
gaatgcgcaa accaaccctt ggcagaacat atccatcgcg tccgccatct ccagcagccg 3780
cacgcggcgc atctcgggca gcgttgggtc ctggccacgg gtgcgcatga tcgtgctcct 3840
gtcgttgagg acccggctag gctggcgggg ttgccttact ggttagcaga atgaatcacc 3900
gatacgcgag cgaacgtgaa gcgactgctg ctgcaaaacg tctgcgacct gagcaacaac 3960
atgaatggtc ttcggtttcc gtgtttcgta aagtctggaa acgcggaagt cagcgccctg 4020
caccattatg ttccggatct gcatcgcagg atgctgctgg ctaccctgtg gaacacctac 4080
atctgtatta acgaagcgct ggcattgacc ctgagtgatt tttctctggt cccgccgcat 4140
ccataccgcc agttgtttac cctcacaacg ttccagtaac cgggcatgtt catcatcagt 4200
aacccgtatc gtgagcatcc tctctcgttt catcggtatc attaccccca tgaacagaaa 4260
ttcccccttta cacggaggca tcaagtgacc aaacaggaaa aaaccgccct taacatggcc 4320
cgctttatca gaagccagac attaacgctt ctggagaaac tcaacgagct ggacgcggat 4380
gaacaggcag acatctgtga atcgcttcac gaccacgctg atgagcttta ccgcagctgc 4440
ctcgcgcgtt tcggtgatga cggtgaaaac ctctgacaca tgcagctccc ggagacggtc 4500
acagcttgtc tgtaagcgga tgccgggagc agacaagccc gtcagggcgc gtcagcgggt 4560
gttggcgggt gtcggggcgc agccatgacc cagtcacgta gcgatagcgg agtgtatact 4620
ggcttaacta tgcggcatca gagcagattg tactgagagt gcaccatatg cggtgtgaaa 4680
taccgcacag atgcgtaagg agaaaatacc gcatcaggcg ctcttccgct tcctcgctca 4740
ctgactcgct gcgctcggtc gttcggctgc ggcgagcggt atcagctcac tcaaaggcgg 4800
taatacggtt atccacagaa tcaggggata acgcaggaaa gaacatgtga gcaaaaggcc 4860
agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc gtttttccat aggctccgcc 4920
cccctgacga gcatcacaaa aatcgacgct caagtcagag gtggcgaaac ccgacaggac 4980
tataaagata ccaggcgttt ccccctggaa gctccctcgt gcgctctcct gttccgaccc 5040
tgccgcttac cggatacctg tccgcctttc tcccttcggg aagcgtggcg ctttctcata 5100
gctcacgctg taggtatctc agttcggtgt aggtcgttcg ctccaagctg ggctgtgtgc 5160
acgaaccccc cgttcagccc gaccgctgcg ccttatccgg taactatcgt cttgagtcca 5220
acccggtaag acacgactta tcgccactgg cagcagccac tggtaacagg attagcagag 5280
cgaggtatgt aggcggtgct acagagttct tgaagtggtg gcctaactac ggctacacta 5340
gaaggacagt atttggtatc tgcgctctgc tgaagccagt taccttcgga aaaagagttg 5400
gtagctcttg atccggcaaa caaaccaccg ctggtagcgg tggttttttt gtttgcaagc 5460
agcagattac gcgcagaaaa aaaggatctc aagaagatcc tttgatcttt tctacggggt 5520
ctgacgctca gtggaacgaa aactcacgtt aagggatttt ggtcatgaga ttatcaaaaa 5580
ggatcttcac ctagatcctt ttaaattaaa aatgaagttt taaatcaatc taaagtatat 5640
atgagtaaac ttggtctgac agttaccaat gcttaatcag tgaggcacct atctcagcga 5700
tctgtctatt tcgttcatcc atagttgcct gactccccgt cgtgtagata actacgatac 5760
gggagggctt accatctggc cccagtgctg caatgatacc gcgagaccca cgctcaccgg 5820

```
ctccagattt atcagcaata aaccagccag ccggaagggc cgagcgcaga agtggtcctg 5880
caactttatc cgcctccatc cagtctatta attgttgccg ggaagctaga gtaagtagtt 5940
cgccagttaa tagtttgcgc aacgttgttg ccattgctgc aggcatcgtg gtgtcacgct 6000
cgtcgtttgg tatggcttca ttcagctccg gttcccaacg atcaaggcga gttacatgat 6060
cccccatgtt gtgcaaaaaa gcggttagct ccttcggtcc tccgatcgtt gtcagaagta 6120
agttggccgc agtgttatca ctcatggtta tggcagcact gcataattct cttactgtca 6180
tgccatccgt aagatgcttt tctgtgactg gtgagtactc aaccaagtca ttctgagaat 6240
agtgtatgcg gcgaccgagt tgctcttgcc cggcgtcaat acgggataat accgcgccac 6300
atagcagaac tttaaaagtg ctcatcattg gaaaacgttc ttcggggcga aaactctcaa 6360
ggatcttacc gctgttgaga tccagttcga tgtaacccac tcgtgcaccc aactgatctt 6420
cagcatcttt tactttcacc agcgtttctg ggtgagcaaa aacaggaagg caaaatgccg 6480
caaaaaaggg aataagggcg acacggaaat gttgaatact catactcttc ctttttcaat 6540
attattgaag catttatcag ggttattgtc tcatgagcgg atacatattt gaatgtattt 6600
agaaaaataa acaaataggg gttccgcgca catttccccg aaaagtgcca cctgacgtct 6660
aagaaaccat tattatcatg acattaacct ataaaaatag gcgtatcacg aggccctttc 6720
gtcttcaaga a                                                      6731
```

<210> 8
<211> 10181
<212> DNA
<213> Artificial Sequence

<220>
<223> plasmid - pDX17R

<400> 8

```
gaattttgcg gccgcttcga aagctgtaat ataaaaacct tcttcaacta acggggcagg 60
ttagtgacat tagaaaaccg actgtaaaaa gtacagtcgg cattatctca tattataaaa 120
gccagtcatt aggcctatct gacaattcct gaatagagtt cataaacaat cctgcatgat 180
aaccatcaca aacagaatga tgtacctgta aagatagcgg taaatatatt gaattacctt 240
tattaatgaa ttttcctgct gtaataatgg gtagaaggta attactatta ttattgatat 300
ttaagttaaa cccagtaaat gaagtccatg gaataataga aagagaaaaa gcattttcag 360
gtataggtgt tttgggaaac aatttccccg aaccattata tttctctaca tcagaaaggt 420
ataaatcata aaactctttg aagtcattct ttacaggagt ccaaatacca gagaatgttt 480
tagatacacc atcaaaaatt gtataaagtg gctctaactt atcccaataa cctaactctc 540
cgtcgctatt gtaaccagtt ctaaaagctg tatttgagtt tatcaccctt gtcactaaga 600
aaataaatgc agggtaaaat ttatatcctt cttgttttat gtttcggtat aaaacactaa 660
tatcaatttc tgtggttata ctaaaagtcg tttgttggtt caaataatga ttaaatatct 720
cttttctctt ccaattgtct aaatcaattt tattaaagtt catttgatat gcctcctaaa 780
tttttatcta aagtgaattt aggaggctta cttgtctgct ttcttcatta gaatcaatcc 840
ttttttaaaa gtcaatatta ctgtaacata aatatatatt ttaaaaatat cccactttat 900
ccaattttcg tttgttgaac taatgggtgc tttagttgaa gaataaagac cacattaaaa 960
aatgtggtct tttgtgtttt tttaaaggat ttgagcgtag cgaaaaatcc ttttctttct 1020
tatcttgata ataagggtaa ctattgaatt cggtaccaag agtttgtaga aacgcaaaaa 1080
ggccatccgt caggatggcc ttctgcttaa tttgatgcct ggcagtttat ggcgggcgtc 1140
ctgcccgcca ccctccgggc cgttgcttcg caacgttcaa atccgctccc ggcggatttg 1200
tcctactcag gagagcgttc accgacaaac aacagataaa acgaaaggcc cagtctttcg 1260
actgagcctt tcgttttatt tgatgcctgg cagttcccta ctctcgcatg gggagacccc 1320
acactaccat cggcgctacg gcgtttcact tctgagttcg gcatggggtc aggtgggacc 1380
accgcgctac tgccgccagg caaattctgt tttatcagac cgcttctgcg ttctgattta 1440
atctgtatca ggctgaaaat cttctctcat ccgccaaaac aggatcctca actgttttat 1500
acaagtgcct tttgcttata ttcctcaacc atttcaacaa acagctgcgt cactcggtga 1560
tcttctgtca gctccggatg gaatgagcag ccaaggaatt gcccctgttt cgcggctaca 1620
atacgaccat tatgctccga tagaacttca acattttcac cagcttctaa aatatgcgga 1680
gcacggatga ataccccagt aaaaggctcg tccaagcctt taattgttaa atcagcttca 1740
aagctgtcaa cctgccggcc aaatgaatta cgttctacaa ccacattcag aagacctaaa 1800
tgaggattat ctgaaccggc aatttctttt gctaatataa ttaatccggc acatgttcca 1860
aacatcggtt tgccctgagc agcgaattca cgaagcggct ccatgaattg atacgtatcg 1920
atcaaacggc gcatcgtcgt gctctcaccg cccggcaaaa tcaacccgtc aacttcgttc 1980
```

agctgctccg gacgttttac gacaagacca gccgcgccgc atgcttcaat cgcatggatg 2040
tgctctctaa ctgctccttg aagtcctagt acacctattg ttaacatgtc agcagcgctc 2100
ctatgttctt accagccgcg ttcttgcata cgctgttctg gaagtaagtt tgagatttca 2160
atccctttca ttgcagtacc aagctctttt gacaactcag cgattaattt gtaatcagta 2220
aagtgagttg ttgcttccac aattgctttc gcaaatttag cagggttgtc tgatttaaaa 2280
ataccagaac caacaaatac tccgtcagca ccaagctgca tcatgagagc agcatcagct 2340
ggagttgcta cgccgccagc ggcaaagtta acgacaggaa gcttgccgtc tttttaatt 2400
tgaagaagaa gctcgtaagg agcacctagg tttttcgctt ctgtcattag ctcatcctca 2460
ctcatcgcaa ctactttgcg cacttgagcg ttaactttac gcatatggcg aacagcctca 2520
acaatattac ctgttccagg ctcacctttt gtgcgaagca tagaagcacc ttccgcaata 2580
cggcgtgttg cttcaccaag atcacggcag ccacagacaa aaggaactgt gtattcattt 2640
ttatttaaat gaaattcttc gtcagccggc gtcagaactt cactttcatc aatatagtca 2700
acacccatag cttcaagcac acgcgcttca acaatatgtc cgatacgcgc ttttgccatt 2760
accgggatag atactgcatt cattacttct tccacgattg tagggtcagc catacgggca 2820
actcctccag ccgcgcgaat atctgctggc acacgttcta gcgccattac agcgacagct 2880
ccagcttctt cagcgatttt cgcttgttcc gcattgatga cgtccatgat gacgccgcct 2940
ttttgcattt ctgccattcc gcgttttaca cgttcagtac ctgtttgagc catgtttttct 3000
cctcctctag aacaggcggg gttgcccccg cctgtaatta aattattaca caccctgtag 3060
ggaaagtcaa tacctttttg taaaattttt acacagcgtg gatctcttct agggacacct 3120
ctttgtaccc ctcaagggag aaatattggc ggtactgagc acagttttgg ttggtggaca 3180
gtgaaccata gctgtcgtca atagcctcga gttatggcag ttggttaaaa ggaaacaaaa 3240
agaccgtttt cacacaaaac ggtctttttc gatttctttt tacagtcaca gccacttttg 3300
caaaaaccgg acagcttcat gccttataac tgctgtttcg gtcgacgatg atctgccgtt 3360
ttcttctgca agccaaaaaa ccttccgtta caacgagaag gattcttcac tttctaaagt 3420
tcggcgagtt tcatccctct gtcccagtcc ttttttggat caaggcagac tgctgcaatg 3480
tctatctatt ttaataatag gtgcagttcg caggcgatac tgcccaatgg aagtatacca 3540
aaatcaacgg gcttgtacca acacattagc ccaattcgat atcggcagaa tagatttttt 3600
taatgccttc gttcgtttct aaaagcagaa cgccttcatc atctatacct aacgccttac 3660
cgtaaaaggt tccgtttaac gttctggctc tcatattagt gccaataccg agcgcatagc 3720
tttcccataa aagcttaatc ggcgtaaatc cgtgcgtcat ataatcccgg taccgtttct 3780
caaagcatag taaaatatgc tggatgacgc cggcccgatc aatttttttcc ccagcagctt 3840
ggctgaggct tgtcgcgatg tccttcaatt catctggaaa atcattaggc tgctggttaa 3900
cgttaatgcc gatcccaatg atcactgaac gtacgcggtc ttcttcagcc tgcatttccg 3960
ttaggatacc gactgttttt tttccgttaa tcaaaatatc atttggccat ttaatatccg 4020
tttggatgcc tgctgcctct tctattccct gcacaacagc tactgcagca agcagagtca 4080
gctgcggtgt tttttggagc ggaatgtcag gccgcaaaat caggctcatc caaacaccgt 4140
ttccttcttg agaatgccat accctagaca ttcggcccct tccggctgtt tgtttgtcag 4200
ccaccacaag ggtgccttcc ggtgcgttat tattcgcgag ctcatgagcc gttttttgcg 4260
tgcttgaaag aacgtcatgg taaataagat gctggcccat cacttccgtt tttaatccaa 4320
aacgaatttc gctttcactg agttttccgg gtttttttgat gagccgatat ccttttcttc 4380
taacggcttc tacttcataa ccctctttcc gaagctcttc aatatgcttc cacacagcag 4440
ttcttgaaca gccgagagca tcactgattt tttggccgga aataaattca ttgccggcct 4500
gagaaaataa ttcaataagg tcttttctta atgttgaccg catgtcttca gccactcctc 4560
tatgtgtttc ttttgattgg agagcttccc tgtcacaaca gcctgctcga tccactgtaa 4620
ttcttctgac acccattttc cggccggccg gtttcgaagc gcaagcaagt ccttacccgt 4680
gatatcaaga tccttaaggc ttttgatcgg caggttttga taagcgtact gaatgtcctt 4740
cagtttcttt tcatccagtt tttcgttttg ccgaagctgc gatattttgg ccgctgagag 4800
cagtgctttt ttcccagctc tgtacattgt cattgcgtca aggctctggc caaacgtatc 4860
ggcaatgtga atggcttcct tgatcacttt tcccgggagc ttccaggctt tcaggaaaag 4920
gggcgcgtct ttcaaaacta tgccaaggtt aattaaaaga gcagcccaaa gctcctcacg 4980
ggatgttaaa gagaagaatg gaaactcact cgttgaaatc aggttttctc gtttatgata 5040
aaaaccagga agctcttcat acaatctcgt ttgaatgagt gtttgaagcg cctggcgaga 5100
agctcttccc tgcagcaatt tctcaaactc tatagttttt cgttcgactg aaacatggga 5160
gaggagtgat ttttctttcg caatggcttc ttctgtttcc ggtgaaagcg taaagccaag 5220
ctggctcata aagcgtacgg ctctcagcat acgaagcgca tcctcttgaa atctatcctc 5280
aggctttcca acggttcgaa tcactttctg atcaatatct ttcttgccgc caaaataatc 5340
aagcaccttc ccgtccgctg tcatggccat cgcattgatc gttaaatctc tgcgttttag 5400
atcctcttct aatgatgaga taaattgcac ttctgacggt cttctgaaat caacataatc 5460
agattcagtc cggaatgtcg tgacttcata ggtttcatcc tcccagagca caataatggt 5520
cccgtgctct ttgcctacat caacagtccg ctgaaacagc cgttctactt gatcaggtgc 5580
cgcatctgtc gcgatatcga catctccgat cgttcgtttc atatagctgt cacgaactgc 5640

gcccccgaca aaataagcct gatggcccgc ttcgattaag atgcggagca cgggaagtgc 5700
tttgataaaa actttttcca tgtgatcact ccggttctgc taaatcggca taaatctgtt 5760
catactggct gacaattttt ttagaagaaa attcattttc aagcatctct attgccgcct 5820
ttgtaaaacg attgcttagc tgttcatctt ctaaaatgct catcgcgcgg gctgttgcgg 5880
ccgtaacatc accgacatcc accaaaaatc cgctcacatt gtttttttata acctcaggga 5940
taccgccaat gtttgttcca atacaaggca ctccgcaagc catcgcttca agcaggacaa 6000
ggccaaagct ttctttttca gatagcagca gcttcaaatc gctaatagaa taaagatctt 6060
caacacggtc ttgatttcca agcattaaga cttggtcttc caagccatat tttctgataa 6120
gctcgcaggc tgtcgatttc tccggaccgt ctccgactaa aagcagcttc gctttcgttt 6180
tgccagcgat attgcggaac acacggatga catcctgcac gcgtgcagcc actggtaaca 6240
ggattagcag agcgaggtat gtaggcggtg ctacagagtt cttgaagtgg tggcctaact 6300
acggctacac tagaaggaca gtatttggta tctgcgctct gctgaagcca gttaccttcg 6360
gaaaaagagt tggtagctct tgatccggca aacaaaccac cgctggtagc ggtggttttt 6420
ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat cctttgatct 6480
tttctacggg gtctgacgct cagtggaacg aaaactcacg ttaagggatt ttggtcatga 6540
gattatcaaa aaggatcttc acctagatcc ttttaaatta aaaatgaagt tttaaatcaa 6600
tctaaagtat atatgagtaa acttggtctg acagttacca atgcttaatc agtgaggcac 6660
ctatctcagc gatctgtcta tttcgttcat ccatagttgc ctgactcccc gtcgtgtaga 6720
taactacgat acgggagggc ttaccatctg gccccagtgc tgcaatgata ccgcgagacc 6780
cacgctcacc ggctccagat ttatcagcaa taaaccagcc agccggaagg gccgagcgca 6840
gaagtggtcc tgcaacttta tccgcctcca tccagtctat taattgttgc cgggaagcta 6900
gagtaagtag ttcgccagtt aatagtttgc gcaacgttgt tgccattgct acaggcatcg 6960
tggtgtcacg ctcgtcgttt ggtatggctt cattcagctc cggttcccaa cgatcaaggc 7020
gagttacatg atcccccatg ttgtgcaaaa aagcggttag ctccttcggt cctccgatcg 7080
ttgtcagaag taagttggcc gcagtgttat cactcatggt tatggcagca ctgcataatt 7140
ctcttactgt catgccatcc gtaagatgct tttctgtgac tggtgagtac tcaaccaagt 7200
cattctgaga atagtgtatg cggcgaccga gttgctcttg cccggcgtca atacgggata 7260
ataccgcgcc acatagcaga actttaaaag tgctcatcat tggaaaacgt tcttcggggc 7320
gaaaactctc aaggatctta ccgctgttga gatccagttc gatgtaaccc actcgtgcac 7380
ccaactgatc ttcagcatct tttactttca ccagcgtttc tgggtgagca aaaacaggaa 7440
ggcaaaatgc cgcaaaaaag ggaataaggg cgacacggaa atgttgaata ctcatactct 7500
tcctttttca atattattga agcatttatc agggttattg tctcatgagc ggatacatat 7560
ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg cacatttccc cgaaaagtgc 7620
cacctgacgt ctaagaaacc attattatca tgacattaac ctataaaaat aggcgtatca 7680
cgaggccctt tcgtctcgca tgcggatcag tgagggtttg caactgcggg tcaaggatct 7740
ggatttcgat cacggcacga tcatcgtgcg ggagggcaag ggctccaagg atcgggcctt 7800
gatgttaccc gagagcttgg cacccagcct gcgcgagcag gggaattgat ccggtggatg 7860
acctttttgaa tgacctttaa tagattatat tactaattaa ttggggaccc tagaggtccc 7920
ctttttttatt ttaaaaattt tttcacaaaa cggtttacaa gcataacggg ttttgctgcc 7980
cgcaaacggg ctgttctggt gttgctagtt tgttatcaga atcgcagatc cggcttcagg 8040
tttgccggct gaaagcgcta tttcttccag aattgccatg atttttttccc cacgggaggc 8100
gtcactggct cccgtgttgt cggcagcttt gattcgataa gcagcatcgc ctgtttcagg 8160
ctgtctatgt gtgactgttg agctgtaaca agttgtctca ggtgttcaat ttcatgttct 8220
agttgctttg ttttactggt ttcacctgtt ctattaggtg ttacatgctg ttcatctgtt 8280
acattgtcga tctgttcatg gtgaacagct ttaaatgcac caaaaactcg taaaagctct 8340
gatgtatcta tcttttttac accgttttca tctgtgcata tggacagttt tccctttgat 8400
atctaacggt gaacagttgt tctacttttg tttgttagtc ttgatgcttc actgatagat 8460
acaagagcca taagaacctc agatccttcc gtatttagcc agtatgttct ctagtgtggt 8520
tcgttgtttt tgcgtgagcc atgagaacga accattgaga tcatgcttac tttgcatgtc 8580
actcaaaaat tttgcctcaa aactggtgag ctgaattttt gcagttaaag catcgtgtag 8640
tgtttttctt agtccgttac gtaggtagga atctgatgta atggttgttg gtattttgtc 8700
accattcatt tttatctggt tgttctcaag ttcggttacg agatccattt gtctatctag 8760
ttcaacttgg aaaatcaacg tatcagtcgg gcggcctcgc ttatcaacca ccaatttcat 8820
attgctgtaa gtgtttaaat ctttacttat tggtttcaaa acccattggt taagcctttt 8880
aaactcatgg tagttatttt caagcattaa catgaactta aattcatcaa ggctaatctc 8940
tatatttgcc ttgtgagttt tcttttgtgt tagttctttt aataaccact cataaatcct 9000
catagagtat ttgttttcaa aagacttaac atgttccaga ttatatttta tgaatttttt 9060
taactggaaa agataaggca atatctcttc actaaaaact aattctaatt tttcgcttga 9120
gaacttggca tagtttgtcc actggaaaat ctcaaagcct ttaaccaaag gattcctgat 9180
ttccacagtt ctcgtcatca gctctctggt tgctttagct aatacaccat aagcattttc 9240
cctactgatg ttcatcatct gagcgtattg gttataagtg aacgataccg tccgttcttt 9300

ccttgtaggg ttttcaatcg tggggttgag tagtgccaca cagcataaaa ttagcttggt 9360
ttcatgctcc gttaagtcat agcgactaat cgctagttca tttgctttga aaacaactaa 9420
ttcagacata catctcaatt ggtctaggtg attttaatca ctataccaat tgagatgggc 9480
tagtcaatga taattactag tccttttcct ttgagttgtg ggtatctgta aattctgcta 9540
gacctttgct ggaaaacttg taaattctgc tagaccctct gtaaattccg ctagaccttt 9600
gtgtgttttt tttgtttata ttcaagtggt tataatttat agaataaaga aagaataaaa 9660
aaagataaaa agaatagatc ccagccctgt gtataactca ctactttagt cagttccgca 9720
gtattacaaa aggatgtcgc aaacgctgtt tgctcctcta caaaacagac cttaaaaccc 9780
taaaggctta agtagcaccc tcgcaagctc gggcaaatcg ctgaatattc cttttgtctc 9840
cgaccatcag gcacctgagt cgctgtcttt ttcgtgacat tcagttcgct gcgctcacgg 9900
ctctggcagt gaatgggggt aaatggcact acaggcgcct tttatggatt catgcaagga 9960
aactacccat aatacaagaa aagcccgtca cgggcttctc agggcgtttt atggcgggtc 10020
tgctatgtgg tgctatctga ctttttgctg ttcagcagtt cctgccctct gattttccag 10080
tctgaccact tcggattatc ccgtgacagg tcattcagac tggctaatgc acccagtaag 10140
gcagcggtat catcaacagg cttacccgtc ttactgtcaa c 10181

<210> 9
<211> 194
<212> DNA
<213> Artificial Sequence

<220>
<223> promoter sequence

<400> 9
gctattgacg acagctatgg ttcactgtcc accaaccaaa actgtgctca gtaccgccaa 60
tatttctccc ttgaggggta caaagaggtg tccctagaag agatccacgc tgtgtaaaaa 120
ttttacaaaa aggtattgac tttccctaca gggtgtgtaa taatttaatt acaggcgggg 180
gcaaccccgc ctgt 194

<210> 10
<211> 163
<212> DNA
<213> Artificial Sequence

<220>
<223> promoter sequence

<400> 10
gcctacctag cttccaagaa agatatccta acagcacaag agcggaaaga tgttttgttc 60
tacatccaga acaacctctg ctaaaattcc tgaaaaattt tgcaaaaagt tgttgacttt 120
atctacaagg tgtggtataa taatcttaac aacagcagga cgc 163

<210> 11
<211> 127
<212> DNA
<213> Artificial Sequence

<220>
<223> promoter sequence

<400> 11
gaggaatcat agaattttgt caaaataatt ttattgacaa cgtcttatta acgttgatat 60
aatttaaatt ttatttgaca aaaatgggct cgtgttgtac aataaatgta gtgaggtgga 120
tgcaatg 127

<210> 12
<211> 42
<212> DNA

<213> Artificial Sequence

<220>
<223> ribosome binding site

<400> 12
gaaatcatat aactatacct tgattagggg gaccaagaaa tg 42

<210> 13
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> ribosome binding site

<400> 13
caagaacgcg gctggtaaga acataggagc gctgctgaca tg 42

<210> 14
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> ribosome binding site

<400> 14
tctagaaagg aggtga 16

<210> 15
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> ribosome binding site

<400> 15
tctagaagga ggagaaaaca tg 22

<210> 16
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> ribosome binding site

<400> 16
tctagaggag gagaaaacat g 21

<210> 17
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> ribosome binding site

<400> 17

taagaacaaa ggaggagagc tgacatg 27

<210> 18
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> ribosome binding site

<400> 18
taagaacaga ggaggagagc tgacatg 27

<210> 19
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> ribosome binding site

<400> 19
taagaagaaa ggaggtgagc tgacatg 27